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Abstract
Hypogonadism negatively impacts various psychological aspects of a male’s life. Males
under the age of 50 who experience symptoms of depression or a decreased sense of
well-being may not be aware that secondary hypogonadism might be the underlying
cause. A gap exists in the literature regarding the psychological effects of testosterone
replacement therapy used to treat hypogonadism. The current research project was
framed by Engel’s biopsychosocial theory, which encompasses the biological,
psychological, and social aspects of a client’s life. The research objective was to
determine the relationship between testosterone replacement therapy and the
psychological effects of depression and quality of life amongst males under the age of 50
who have been diagnosed with secondary hypogonadism. Secondary data were gathered
on 17 males with the assistance of a health clinic on the East Coast of the United States.
Statistically significant differences were found in the reported levels of depression and
quality of life. This study provides additional guidance to clinical psychologists, primarycare physicians, psychiatrists, pediatricians, endocrinologists, and internal medicine
specialists who see males under the age 50 in their practice settings. The results of this
study could influence positive social change by increasing awareness of a medical issue
that can mimic symptoms of depression and anxiety.
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Chapter 1: Introduction to the Study
Secondary hypogonadism occurs when the hypothalamus or pituitary gland fails
to produce an adequate amount of testosterone (Akturk & Nippolt, 2016; Dudek et al.,
2017; Plessis, et al., 2019; Tarnutzer, 2015). Known causes of secondary hypogonadism
include genetic defects, severe stress, drug use, long-term medical diseases, or damage to
the hypothalamus or pituitary gland (Bhasin et al., 2018; Dhindsa et al., 2018; Forni &
Wray, 2015; Issacs & Thomas, 2015; Lasaite et al., 2016; McCullough, 2015). Secondary
hypogonadism adversely affects specific psychological aspects of a male’s life including
introducing or increasing symptoms of depression and reducing quality of life (Akturk &
Nippolt, 2016; Izzo, 2016; Lasaite et al., 2016; Plessis et al., 2019; Shiraishi et al., 2014).
One possible treatment for secondary hypogonadism is testosterone replacement therapy
(Barton et al., 2016; Jung & Shin, 2016; Morales et al., 2015; Sterling et al., 2015).
However, there is only limited research about the psychological effects of this treatment
method (Aydogan et al., 2012; Konaka et al., 2016; Lee & Tillman, 2016).
In the current quantitative study, I analyzed the psychological effects of
testosterone replacement therapy for males under the age of 50, with secondary
hypogonadism, over a 2-month period. The study has several implications for positive
social change which include (a) providing a scholarly contribution to the sparse research
on this important subject; (b) increasing awareness of a medical issue that can mimic
symptoms of depression, anxiety, and various other diagnoses described in the
Diagnostic and Statistical Manual of Mental Disorders (5th ed.; DSM-5; American
Psychiatric Association [APA], 2013); and (c) providing an assessment of the
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psychological effects and efficacy of a largely unexamined invasive treatment option on
an underserved population (Issacs & Thomas, 2015; Kim et al., 2016; Lee & Tillman,
2016; Veras & Nardi, 2010).
In Chapter 1, I provide background information on the psychological effects of
testosterone replacement therapy for males with secondary hypogonadism. This chapter
also includes a presentation of the research problem, the quantitative design and variables
of the current study, and the research questions (RQs) and hypotheses. The purpose and
nature of the study, the methodology and theoretical orientation, and definitions for key
terms and constructs operationalized in the study are included as well. I also address the
assumptions, scope and delimitations, limitations, significance, and social change
implications before providing a summary of the chapter.
Background
Hypogonadism, more commonly known as low testosterone, is a medical issue
that primarily impacts the male population (Bandari et al., 2017; Basaria, 2014; Bhasin et
al., 2018; Winters & Huhtaniemi, 2017). The condition occurs when the body fails to
create an adequate amount of testosterone (Basaria, 2014; Bhasin et al., 2010;
Morgentaler et al., 2016). Although a significant number of males are directly impacted
by hypogonadism, not everyone is cognizant that the issue exists (Basaria, 2014; Bhasin
et al., 2010; Winters & Huhtaniemi, 2017). Some males are aware that they have
hypogonadism, while others are unaware of the medical issue because the symptoms
result from or mimic other psychological concerns and conditions (Basaria, 2014; Bhasin
et al., 2018; Lee & Tillman, 2016; Tanriverdi & Kelestimur, 2015). Although

3
hypogonadism can affect males at any age, it is more commonly looked at and tested for
in older males because testosterone levels naturally decrease with age (Akturk &
Nippoldt, 2016; Busnelli et al., 2017; Cohen et al., 2020; Dudek et al., 2017; Hackett,
2016; Huo et al., 2016; Mascarenhas et al., 2016; Nian et al., 2017; Yazdani & Branch,
2018).
Subcategories of hypogonadism include both primary (hypergonadotropic
hypogonadism) and secondary (hypogonadotropic hypogonadism) types (Akturk &
Nippolt, 2016; Basaria, 2014; Javed et al., 2015; Lee & Tillman, 2016; Morales et al.,
2015; Plessis et al., 2019; Sterling et al., 2015). Primary hypogonadism means that the
inner workings of the pituitary gland or hypothalamus are functioning as they should, but
there is a problem or issue with the testicles (Basaria, 2014; Bhasin et al., 2018; Javed et
al., 2015; Lee & Tillman, 2016; Sterling et al., 2015; Winters & Huhtaniemi, 2017).
Secondary hypogonadism means that the testicles are functioning as they should, but
there is a problem or issue with the inner workings of the pituitary gland or hypothalamus
(Akturk & Nippolt, 2016; Bhasin et al., 2018; Dudek et al., 2017; Plessis et al., 2019;
Winters & Huhtaniemi, 2017). In the current study, I was interested in secondary
hypogonadism, which results from damage to the hypothalamic-pituitary region of the
brain (Akturk & Nippolt, 2016; Barton et al., 2016; Plessis et al., 2019; Taylor et al.,
2017). Figure 1 provides an illustration of primary and secondary hypogonadism.
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Figure 1
An Illustration of Primary and Secondary Hypogonadism

Note. (K. Davis, personal communication, May 14, 2021). Reprinted with permission
(see Appendix A).

Secondary hypogonadism can result from various congenital or acquired issues
including Kallmann syndrome and traumatic brain injury (Barton et al., 2016; Dwyer et
al., 2019; Forni & Wray, 2015; Maione et al, 2018; Ruiz et al., 2016; Sterling et al., 2015;
Taylor et al., 2017; Tritos et al., 2015). Kallmann syndrome is a congenital condition
resulting from the deficient production of certain hormones produced in the
hypothalamus (Dwyer et al., 2019; Maione et al., 2018; Ruiz et al., 2016). Traumatic
brain injury is an acquired condition resulting from sudden physical damage to the brain
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(Hackenberg & Unterberg, 2016). At the time of this study, a gap existed in the literature
regarding the psychological effects of testosterone replacement therapy for males under
the age of 50 with secondary hypogonadism (Hackett, 2016; Izzo, 2016; Konaka et al.,
2016; Lee & Tillman, 2016). In the current study, I addressed this gap in the literature.
Problem Statement
For an average male, the typical range of testosterone is between 250 and 950
nanograms per deciliter (Bhasin et al., 2018; Morales et al., 2015; Saad et al., 2016;
Sterling et al., 2015). When the testosterone level becomes deficient, the male with
secondary hypogonadism tends to experience negative sexual and somatic effects (Akturk
& Nippolt, 2016; Aydogan et al., 2012; Dhindsa et al., 2018; Hackett, 2016; Lee &
Tillman, 2016; Snyder et al., 2016; Yassin et al., 2016). Secondary hypogonadism also
negatively impacts various psychological aspects of a male’s life including introducing or
increasing symptoms of depression and decreasing the quality of life (Akturk & Nippolt,
2016; Aydogan et al., 2012; Huo et al., 2016; Hwang & Miner, 2015; Javed et al., 2015;
Lasaite et al., 2016; Morales et al., 2015; Shiraishi et al., 2014; Uddin et al., 2017).
Testosterone replacement therapy is a viable option to treat and ameliorate the
undesired psychological affects commonly associated with secondary hypogonadism
(Barton et al., 2016; Cherrier et al., 2015; Mohamad et al., 2018; Morales et al., 2015). A
small amount of research exists on the psychological effects of testosterone replacement
therapy, but this literature primarily focuses on the aging male population, which is
comprised of individuals diagnosed as having late-onset hypogonadism (Busnelli et al.,
2017; Cherrier et al., 2015; Dudek et al., 2017; Hackett, 2016; Konaka et al., 2016; Lee &
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Tillman, 2016; Snyder et al., 2016). This lack of research on young men is concerning
because age is not an exemption from secondary hypogonadism (Aydogan et al., 2012;
Bouvattier & Young, 2020; Dhindsa et al., 2018; Forni & Wray, 2015; Lucas-Herald,
2018). For example, a young adult who plays football in college or an adolescent who
falls off their bicycle could have head trauma and not realize it. Not every individual who
participates in contact sports or hits their head will end up with a traumatic brain injury
resulting in secondary hypogonadism, but for some it is a possibility and reality (Rey &
Grinspon, 2020).
Males under the age of 50 who experience depressive symptoms or a decreased
sense of well-being may not be aware that hypogonadism might be a possible cause
(Basaria, 2014; Bhasin et al., 2018; Lee & Tillman, 2016; Tanriverdi & Kelestimur,
2015). For males of any age who suffer from negative psychological effects of secondary
hypogonadism, testosterone replacement therapy may be a practical and beneficial
solution (Aydogan et al., 2012; Cherrier et al., 2015; Huo et al., 2016; Lasaite et al.,
2016; Lee & Tillman, 2016; Snyder et al., 2016). Researchers have been quick to
highlight the sexual and somatic effects of testosterone replacement therapy for males
(Hackett, 2016; Huo et al., 2016; Hwang & Miner, 2015; Morales et al., 2015; Yassin et
al., 2016). The problem remains that researchers often overlook the psychological effects
of testosterone replacement therapy for younger males (Hackett, 2016; Huo et al., 2016;
Hwang & Miner, 2015; Morales et al., 2015; Yassin et al., 2016). A lack of scientific
research focused on the younger male population in the literature indicates a need for
additional psychological studies. Clinicians can use the results of the current study to
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evaluate the psychological effects and efficacy of an underanalyzed treatment possibility
for an overlooked, underserved, and susceptible population.
Purpose of the Study
The purpose of this quantitative study was to investigate the psychological effects
of testosterone replacement therapy for males under the age of 50 with secondary
hypogonadism. This study consisted of one independent variable (time exposed to
testosterone replacement therapy) and two dependent variables (quality of life and
depression). Looking at the psychological effects of testosterone replacement therapy for
males under the age of 50 with secondary hypogonadism begins to address the gap in the
current literature (Huo et al., 2016; Konaka et al, 2016; Morales et al, 2015; Shin et al.,
2016). The research objective was to determine the relationship between testosterone
replacement therapy and the psychological effects of depression and quality of life
amongst males under the age of 50 who have been diagnosed with secondary
hypogonadism.
Research Questions and Hypotheses
To achieve the research objective, I investigated the following RQs and
hypotheses:
RQ1: Is the psychological aspect of quality of life significantly affected by
testosterone replacement therapy maturation?
H01: The mean scores for the psychological aspect of quality of life, as assessed
by the Quality of Life Scale (QoLS) do not differ significantly over baseline, 1

8
month, and 2 months of testosterone replacement therapy duration in males under
the age of 50 suffering from secondary hypogonadism.
Ha1: The mean scores for the psychological aspect of quality of life, as assessed
by the QoLS do differ significantly over baseline, 1 month, and 2 months of
testosterone replacement therapy duration in males under the age of 50 suffering
from secondary hypogonadism.
RQ2: Is the psychological aspect of depression significantly affected by
testosterone replacement therapy maturation?
H02: The mean scores for the psychological aspect of depression, as assessed by
the Patient Health Questionnaire-9 (PHQ-9), do not differ significantly over
baseline, 1 month, and 2 months of testosterone replacement therapy duration in
males under the age of 50 suffering from secondary hypogonadism.
Ha2: The mean scores for the psychological aspect of depression, as assessed by
the PHQ-9, do differ significantly over baseline, 1 month, and 2 months of
testosterone replacement therapy duration in males under the age of 50 suffering
from secondary hypogonadism.
Theoretical Framework
The theoretical framework used in this research was Engel’s (1977)
biopsychosocial model (see also Guillemin & Barnard, 2015; Gupta & Venkatesan, 2018;
Jorn, 2015; Pletikosic et al., 2018). Engel introduced his concept in a 1977 article in
which he explained the need for a new medical model (see also Jorn, 2015; Vongas &
Alhaji, 2015; Wade & Halligan, 2017). The biopsychosocial model is an approach that
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considers the significance of analyzing a client within their fullest context (Engel, 1977;
Gupta & Venkatesan, 2018; Wade & Halligan, 2017). Engel’s biopsychosocial model
considers the biological, the psychological, and the social aspects of a client’s life and
how they intertwine with and react to one another (Guillemin & Barnard, 2015; Wade &
Halligan, 2017). The model suggests a correlation between the mind and the body (Engel,
1977; Gupta & Venkatesan, 2018; Vongas & Alhaji, 2015). I discuss this model in more
detail in chapter 2.
Clinicians use the biopsychosocial model to provide structure for client
interaction and as a perspective framework for how they see clients and provide care
(Engel, 1977; Vongas & Alhaji, 2015; Wade & Halligan, 2017). In medical sociology,
sickness is an all-encompassing term with causes such as various microorganisms, any
number of physiological malfunctions, and everyday life (Aydogan et al., 2012; Illiffe,
2017; Pletikosic et al., 2018). Quality of life and depression are factors influenced by
various biological, psychological, and social realms of a client’s life (APA, 2013; Barton,
2016; Burckhardt & Anderson, 2003; Chen et al., 2016). Low testosterone can create
inabilities for an individual in each of the three biopsychosocial realms; this unfortunately
can result in negative somatic, psychological, and social complications (Hackenberg &
Unterberg, 2016; Morales et al., 2015; Vongas & Alhaji, 2015). Low testosterone can
also create a vicious cycle of physical health complications that create mental health
complications and vice versa (Dudek et al., 2017; Grabner et al., 2017; Johansen, 2016;
Morales et al., 2015; Stancampiano et al., 2019).
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Nature of the Study
This study was nonexperimental, quantitative, and correlational in nature.
Quantitative research is an adequate and sufficient approach when determining if a
relationship exists between variables and evaluating various theories (Creswell, 2014;
Morgan et al., 2012). I used a nonexperimental design to determine if relationships
existed between the independent variable (time exposed to testosterone replacement
therapy) and the two dependent variables (quality of life and depression).
I used a repeated measures analysis of variance (rANOVA) design with withinsubject effects (Creswell, 2014; Guo et al., 2013). rANOVA is a statistical method
utilized by researchers to analyze the equality of means across variables that are
fabricated with repeated observation (Creswell, 2014; Guo et al., 2013; Morgan et al.,
2012). One advantage of using a rANOVA is that it involves the same participants, which
means a smaller sample size is acceptable (Guo et al., 2013; Morgan et al., 2012). The
intent and purpose of this rANOVA was to evaluate and see how each of the two
dependent variables (quality of life and depression) were affected by the independent
variable (time exposed to the testosterone replacement therapy). The independent
variable was measured at baseline, 1 month, and 2 months.
I analyzed secondary data from an existing data set. I had no direct contact with
the patients included in the data set, which eliminated various ethical issues. Information
was collected from a health clinic on the East Coast of the United States. This method of
data gathering assured that collected information reflected patients who had low levels of
testosterone and began receiving testosterone replacement therapy at the clinic. In chapter

11
3, I address the research methodology in more detail.
Definitions
Depression: One of the most common mental disorders that results in a constant
state of sadness and loss of interest (APA, 2013). The symptoms of depression cause
distress in a multitude of environments including occupational, academic, professional,
and personal (APA, 2013). Individuals tend to experience an interference with
concentration, motivation, and various aspects of daily functioning (APA, 2013).
Individuals who experience depression may struggle with typical daily routines and
sometimes feel like life is not worth continuing (APA, 2013).
Hypogonadism: A condition that can affect both males and females. For males,
this condition occurs when sperm and/or testosterone deficiencies are present at the
testicular level and/or from within the hypothalamic-pituitary-testicular axis (Bhasin et
al., 2018; Dhindsa et al., 2018; Jung & Shin, 2016; Kim et al., 2016; Lee & Tillman,
2016). Reasons for hypogonadism can be functional or organic in nature (Bhasin et al.,
2018). Functional hypogonadism means that there is a possibility to reverse the condition
if the underlying cause is properly treated (Bhasin et al., 2018). Organic hypogonadism
means that the congenital, structural, genetic, or destructive damage is permanent and not
possible to reverse (Bhasin et al., 2018). Hypogonadism can result from trauma to the
brain or testicles, chemotherapy, anabolic steroid use, various medications, hormone
disorders, and numerous genetic conditions and chronic diseases (Bhasin et al., 2018;
Dhindsa et al., 2018; Jung & Shin, 2016; Kim et al., 2016; Lee & Tillman, 2016).
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Quality of Life: A concept consisting of numerous social, biological, physical,
environmental, and psychological values (Burckhardt & Anderson, 2003; Gelaye et al.,
2016; Nian et al., 2017; Uddin et al., 2017). It is a broad concept that considers how
individuals measure components of their subjective well-being (Barton et al., 2016;
Cooke et al., 2016; Dronavalli & Thompson, 2015; Gelaye et al., 2016; Shiraishi et al.,
2014).
Secondary Hypogonadism: This type of hypogonadism also referred to as
hypogonadotropic or central, describes low testosterone as being due to a malfunctioning
or damaged hypothalamus or pituitary gland (Barton et al., 2016; Dhindsa et al., 2018;
Lasaite et al., 2016; Resnick et al., 2017; Shiraishi et al., 2014). As shown in Figure 2, the
hypothalamus produces the gonadotropin-releasing hormone (GnRH), which then
prompts the pituitary gland to produce the follicle-stimulating hormone (FSH) and the
luteinizing hormone (LH; Aydogan et al., 2012; Bhasin et al., 2010; Forni & Wray, 2015;
Livadas & Chrousos, 2020; Morales et al., 2015). The LH then cues the testes to create
testosterone (Basaria, 2014; Forni & Wray, 2015; Morales et al., 2015; Sterling et al.,
2015).
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Figure 2
Hypothalamic-Pituitary-Gonadal (HPG) Axis

Note. The hypothalamus creates GnRH, which triggers the pituitary gland to create FSH
and LH. From “GnRH, Anosmia, and Hypogonadotropic Hypogonadism: Where Are
We?” by P. Forni and S. Wray, 2015, Frontiers in Neuroendocrinology, 36(1), p. 166
(http://doi:10.1016/j.yfrne.2014.09.004). Copyright 2015 by Forni and Wray. Reprinted
with permission (see Appendix A).
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Testosterone: A hormone found in both males and females that is produced in the
gonads (testes for males and ovaries for females) (Incze & Kompala, 2020; Snyder et al.,
2016). Males produce a much higher quantity than females (Incze & Kompala, 2020).
Males can range from under 20 to over 1,000 nanograms per deciliter (ng/dL), while the
range falls between 10 and 80 ng/dL for a female (Jung & Shin, 2016; Snyder et al.,
2016).
Testosterone Replacement Therapy: An option for men with secondary
hypogonadism (low testosterone), to get their testosterone levels within a generally
accepted normal range (250-950ng/dL Nian et al., 2017; Saad et al., 2016; Shin et al.,
2016; Tsametis & Isidori, 2018). The primary options for administration include
intramuscular, transdermal, and subcutaneous (Lee & Tillman, 2016; Nian et al., 2017;
Ponce et al., 2018). Intramuscular administration is a method used to inject the
testosterone into the client’s muscle (Lee & Tillman, 2016). Advantages include the
reasonable cost and ability for patients to learn how to administer the shot themselves
(Lee & Tillman, 2016). Disadvantages include possible intermediate changes in mood,
soreness, and bruising (Lee & Tillman, 2016). Transdermal administration is a method
using patches, gels, or liquids to distribute the testosterone (Hadgraft & Lane, 2015; Lee
& Tillman, 2016). Advantages include a less invasive method for administration while
disadvantages include daily administration and restrictions when around water, women,
and children (Hadgraft & Lane, 2015; Lee & Tillman, 2016).
Subcutaneous administration is a method where testosterone is either injected into
a layer of fat below the dermis twice a week, or pellets are implanted into the buttocks
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every 3 to 6 months (Lee & Tillman, 2016; Spratt et al., 2017). With the injections,
advantages include less discomfort and pain, smaller needle size, possibly fewer dosages
of testosterone needed to sustain steady state levels of serum testosterone, and a closer
ability to mimic how the body would naturally create testosterone (Lee & Tillman, 2016;
Spratt et al., 2017). Disadvantages include more frequent injections. With the pellets,
advantages include a slower release and less frequent administration cycles, while the
disadvantages include its invasiveness, a possibility for infection, and possible extrusion
(Lee & Tillman, 2016; Spratt et al., 2017).
Assumptions
I assumed that the patients in the study were taking testosterone as prescribed for
their diagnosis of secondary hypogonadism, and that the prescriptions were of adequate
strength. I also assumed that all gathered data were preexisting data from the health
clinic. It was assumed that patients in the secondary data set met the inclusion criteria for
this study. Another assumption was that the patients filled out the forms and self-reports
accurately. It was also assumed all records were as accurate as possible, extending from
the assumption that all staff members involved with collecting data had the clinical
knowledge and competency to do so. Furthermore, I assumed that the patients had no
other comorbidities that could have potentially affected the dependent variables of
depression or quality of life. I also assumed that confidentiality and Health Insurance
Portability and Accountability Act of 1996 rights were maintained by the use of
preexisting data and that the use of these data mitigated potential ethical concerns.
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Scopes and Delimitations
In this study I analyzed the psychological effects of testosterone replacement
therapy for males under the age of 50 with secondary hypogonadism. I chose this topic
for this study because only limited research reports were available regarding the
psychological effects of testosterone replacement therapy for males with secondary
hypogonadism (Barton et al., 2016; Morales et al., 2015; Snyder et al, 2018). The
research gap revealed age as an area of neglect, with the available research primarily
focused on the aging male population and late-onset hypogonadism (Busnelli et al., 2017;
Dudek et al., 2017; Hackett, 2016; Konaka et al., 2016; Lee & Tillman, 2016;
McCullough, 2015; Nian et al., 2017; Saad et al., 2016; Snyder et al., 2016; Sterling et
al., 2015). I addressed this gap in the literature by focusing on males under the age of 50.
Delimitations also existed within this study. The first delimitation was the age
constraint. I was only interested in patients 49 years-of-age and younger. Anyone 50
years of age or older, was excluded from the research. The second delimitation was
gender. I took into account and only analyzed biological males; no females or individuals
who identify as transgender were included in the research. The third delimitation was the
diagnosis of low testosterone. My interest was in males who had been diagnosed with
secondary hypogonadism; any clients diagnosed with primary hypogonadism were
excluded. The fourth delimitation involved the dependent variables; I only looked at the
psychological effects of depression and quality of life. Additional psychological effects
such as mood, aggression, anxiety, and irritability were not analyzed. The final
delimitation was the route of delivery for the testosterone. Patients at the health clinic
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received testosterone by subcutaneous means, meaning that all other routes of delivery
(e.g., transdermal, intramuscular, and oral) were excluded from analysis.
Limitations
Although this research was carefully thought out and executed, certain limitations
and shortcomings were unavoidable. Primary limitations involved time, access to
populations of interest, and use of secondary data. First, I only considered a 2-month
period; more accurate results may have been gathered if participants were analyzed for a
year or longer. Second, I did not have the opportunity or ability to access all populations
of interest. The representative sample was small and may not represent the majority of
males under the age of 50 with secondary hypogonadism on a global level. Third, as
Frankfort-Nachmias et al. (2015) point out, using secondary data is also considered a
limitation. The reason is that the researcher is unable to control how the data are
gathered, generated, and recorded (Frankfort-Nachmias, Nachmias, & DeWaard, 2015).
Relying on other individuals to accurately gather information introduces many
uncertainties, which may be a limitation to this study’s validity (see Frankfort-Nachmias
et al., 2015).
Significance
This study provides an original contribution to the existing literature by infusing
new empirical material that addresses the psychological effects of testosterone
replacement therapy for males under the age of 50 with secondary hypogonadism. In this
way, the study provides a deeper understanding of male hypogonadism from a
psychological perspective. This research may prove significant not only to the plethora of
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individuals who suffer from low testosterone but also to the clinicians and providers who
engage and assist with this population.
This study also challenged the misconception that low testosterone exclusively
correlates with age (see Aydogan et al., 2012; Basaria, 2014; McCullough, 2015). Low
testosterone is more than a naturally occurring phenomenon that occurs within the aging
male population (Lee & Tillman, 2016; McCullough, 2015; Nian et al., 2017; Snyder et
al., 2016). This research highlights an existing population of younger males who acquired
hypogonadism due to malfunctions of the pituitary gland or hypothalamus (Dudek et al.,
2017; Forni & Wray, 2015; Lee & Tillman, 2016). These malfunctions are derived from a
variety of issues, including severe stress, drug use, long-term medical diseases, or
traumatic brain injuries (Barton et al., 2015; Bhasin et al., 2018; Dhindsa et al., 2018;
Forni & Wray, 2015; Issacs & Thomas, 2015; Javed et al., 2015; Lasaite et al., 2016;
McCullough, 2015). I plan to share these findings through various publications and
conferences, as well as within my professional network.
Several implications for positive social change exist within this study. Current
research about testosterone replacement therapy tends to ignore its psychological benefits
(Hackett, 2016; Hwang & Miner, 2015; Morales et al., 2015; Yassin et al., 2016).
Psychological benefits may include, but are not limited to, decreased depressive
symptoms, increased symptoms of well-being, and increased longevity (Morales et al.,
2015; Shin et al., 2016; Shiraishi et al., 2014; Snyder et al., 2016; Yassin et al., 2016).
With more knowledge about the psychological benefits of testosterone replacement
therapy, individuals may be better informed when deciding whether or not testosterone
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replacement therapy is an appropriate decision.
This research brings awareness to psychologists of a medical issue that mimics
symptoms of depression, anxiety, and various other DSM-5 diagnoses (Issacs & Thomas,
2015; Kim et al., 2016; Lee & Tillman, 2016; Samahy et al., 2021; Veras & Nardi, 2010).
This research also brings awareness to neuropsychologists of a medical issue that can
result from traumatic brain injury or mimic its symptoms (Issacs & Thomas, 2015;
Sterling et al., 2015; Tanriverdi et al., 2015). Low testosterone can affect males of any
age (Aydogan et al., 2012; Basaria, 2014; Busnelli et al., 2017; Huo et al., 2016; Jung &
Shin, 2016). It is important for psychologists and neuropsychologists to keep in mind the
relevance of a patient’s medical history before considering a diagnosis (Issacs & Thomas,
2015; Lee & Tillman, 2016). Education and awareness of low testosterone issues allows
for increased accuracy of diagnoses (Issacs & Thomas, 2015; Lee & Tillman, 2016).
Summary
Secondary hypogonadism is a concerning issue for males caused by complications
with the hypothalamus or pituitary gland (Akturk & Nippolt, 2016; Dudek et al., 2017;
Tarnutzer, 2015). Treatment options are available for hypogonadism, which can affect
various psychological features of an individual’s life (Akturk & Nippolt, 2016; Izzo,
2016; Lasaite et al., 2016; Shiraishi et al., 2014). In this chapter I provided a brief
description of the biopsychosocial model as the theoretical framework for this study. I
also introduced the independent and dependent variables and explained how they
intertwine with one another. The independent variable, time exposed to testosterone
replacement therapy, psychologically affects the dependent variables of depression and
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quality of life, according to researchers (Akturk & Nippolt, 2016; Izzo, 2016; Lasaite et
al., 2016; Shiraishi et al., 2014). Material presented in Chapter 1 indicated the existence
of a gap in the literature and the intention and nature of this study. This study contributes
to the scholarly field of psychology by addressing the psychological effects of
testosterone replacement therapy for males under the age of 50 with secondary
hypogonadism. In Chapter 2, I provide a more comprehensive and exhaustive reflection
of the available literature relating to testosterone replacement therapy for those with
hypogonadism. I also address inconsistencies and gaps in the extant literature concerning
the psychological effects of testosterone replacement therapy for males under the age of
50 with secondary hypogonadism.
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Chapter 2: Literature Review
Introduction
For a typical male, the mean range of testosterone falls somewhere between 250
and 950 ng/dL (Morales et al., 2015; Saad et al., 2016; Sterling et al., 2015). If the
testosterone levels become too low, males of any age may experience various
combinations of negative sexual, somatic, and/or psychological symptoms (Akturk &
Nippolt, 2016; Aydogan et al., 2012; Lee & Tillman, 2016; Huo et al., 2016). The
purpose of this study was to go beyond the confines of the current literature and
investigate the psychological effects of testosterone replacement therapy for males under
the age of 50 with secondary hypogonadism over a 2-month period. The focus was on
determining if a relationship existed between the time exposed to testosterone
replacement therapy and levels of quality of life and depression.
The literature review that follows includes information from the most current
research relating to psychological effects of testosterone replacement therapy for males
under the age of 50 who have been diagnosed with secondary hypogonadism. I describe
the literature search strategy and theoretical foundation before reviewing literature on the
key variables and concepts involved in the study. The chapter concludes with a concise
summary of (a) the major themes found in the literature, (b) what is known and not
known in relation to the psychological effects of testosterone replacement therapy for
males under the age of 50 who have been diagnosed with secondary hypogonadism, and
(c) how the current study addresses and fills a gap in the literature and extends
knowledge in the discipline.
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Literature Search Strategy
To explore the literature, I used library resources from Walden University,
University of Phoenix, Oxford University, and University of California-Berkeley. The
specific databases and search engines used to discover the literature included: ASSIA,
BioMed Central, Directory of Open Access Journals, EBSCOhost, Embase, ERIC,
Google Scholar, ORA, Ovid Medline, Oxford Academic, Oxford Scholarship Online,
ProQuest Central, ProQuest Health & Medical, ProQuest Psychology, PsycARTICLES,
PsycEXTRA, PsycINFO, PsycNET, PubMed, SAGE Journals, SAGE Knowledge, SAGE
Premier, SCOPUS, SOLO, and ZETOC. Types of scholarly literature that were reviewed
included systematic reviews, review articles, empirical studies, retrospective studies,
prospective trials, meta-analyses, and peer-reviews. Research analysis included recent
and past peer-reviewed articles and seminal literature. The following key words, terms,
and phrases were used in a variety of combinations: Testosterone, hypogonadism,
hypogonadotropic hypogonadism, testosterone replacement therapy, traumatic brain
injury, depression, quality of life, Patient Health Questionnaire, Quality of Life Scale,
and biopsychosocial. The exhaustive list can be found in Appendix B.
Theoretical Foundation
The theoretical framework and foundation for this study was George Engel’s
(1977) biopsychosocial model which addresses the integration of the biological,
psychological, and social aspects of a client’s life. As Wade and Halligan (2017) pointed
out, the biopsychosocial model provides validity and utility to a generally accepted view
that health is based on an amalgamation of multiple factors. Babolola et al. (2017), along
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with Moss (2018), have noted that the biopsychosocial model allows for a more
integrative cognizance of the biological, psychological, and social elements of an
individuals’ life. The World Health Organization has endorsed the biopsychosocial
approach and its methods for understanding mental health concerns in an inclusive
manner (Babolola et al., 2017; Moss, 2018; Wade & Halligan, 2017).
A number of researchers (e.g., Babalola et al., 2017; Guillemin & Barnard, 2015;
Gupta & Venkatesan, 2018; Register-Mihalik et al., 2020; Wade & Halligan, 2017) have
used the biopsychosocial model. Some researchers have analyzed how the model assists
when working with psychological concerns such as depression or anxiety (Ell et al.,
2015; Moss, 2018). Ell et al. (2015) explored the use of the model for patients displaying
symptoms of depression. Moss (2018) utilized the biopsychosocial approach to show
efficacy in treating anxiety. Some researchers have suggested that a biopsychosocial
approach enhances and increases overall health outcomes (Ell et al., 2015; Wade &
Halligan, 2017). Other researchers have demonstrated how the biopsychosocial model
can assist in explaining concerns and how complications can span more than one aspect
of a client’s life (Iliffe, 2017; Vongas & Alhaji, 2015). Iliffe (2017) used the framework
to explain how dementia affects the biological, psychological, and social aspects of a
client’s life. Vongas and Alhaji (2015) used the framework to explain how testosterone
levels affect a client biologically, psychologically, and socially.
The biopsychosocial model stems from the view of a client’s health being affected
by three different aspects (Benning, 2015; Engel, 1977; Gupta & Venkatesan, 2018;
Kusnanto et al., 2018). As Iliffe (2017) suggested, looking at the biological, social, and
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psychological concerns assists clinicians in administering a more thorough and casespecific treatment. When working from a biopsychosocial approach, a clinician explores
the three aspects (biological, psychological, and social) of the individual’s life, taking
into account micro and the macro perspectives (Iliffe, 2017; Jorn, 2015). As Kusnanto et
al. (2018) suggested, the biopsychosocial model potentially provides a more accurate
diagnosis due to the understanding and awareness of the intertwinement of biological,
psychological, and social components. The biopsychosocial framework can provide a
fundamental route to integrate mental and physical concerns (Melchert, 2011; Pletikosic
et al., 2018; Richter, 1999). The model helps to explain why physiological issues can
sometimes create psychological complications (Wade & Halligan, 2017). Furthermore, it
takes into account a client’s history and symptoms in the context of various life
circumstances and can support a treatment that is multifaceted in nature (Benning, 2015;
Engel, 1977; Kusnanto et al., 2018; Vongas & Alhaji, 2015).
Literature Review of Key Variables and Concepts
Hypogonadism
The majority of research in the literature review, focuses on hypogonadism, also
known as low testosterone, and how it affects the aging male population (e.g., Dudek et
al., 2017; Nian et al., 2017; Snyder et al., 2016; Sterling et al., 2015). Yet, age is not a
deterrent for hypogonadism; anyone of any age can be affected (Aydogan et al., 2012;
Travis, 2015; Sterling et al., 2015). Hypogonadism can begin while a fetus is still in the
womb, during childhood, adolescence, or adulthood (Lee & Tillman, 2016; Morales et
al., 2015; Sterling et al., 2015).
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Recognized as an important condition since the early 1940s, hypogonadism is
broadly defined as a condition where the testicles do not create an adequate amount of
testosterone (Dhindsa et al., 2018; George et al., 2017; Kim et al., 2016). Hypogonadism
is now a well-recognized, medical condition that is known to negatively affect general
health, mental health, sexuality, reproduction, and quality of life (George et al., 2017;
Rosen et al., 2018). Sterling et al. (2015) pointed out that nearly four million men in the
United States are affected by hypogonadism. The definition of hypogonadism has a
variety of sub-classifications based on the age of the individual and the source (Bhasin et
al., 2018; Sterling et al., 2015). For example, hypogonadism sources include: aging,
issues with the thyroid, chemotherapy, and genetic morphing of certain genes (Bhasin et
al., 2018; Snyder et al., 2018). As Akturk et al. (2016) pointed out, failing to identify the
underlying cause of hypogonadism can create further issues and complications.
Hypogonadism is easy to define but tricky to diagnose (see Figure 3); in addition,
treatment is controversial (Bhasin et al., 2018; McBride et al., 2017; Morales et al., 2015;
Sterling et al., 2015; Varimo et al., 2017). Experts have posited two categories of
hypogonadism (primary and/or secondary); it is essential to determine which category of
hypogonadism a client falls under (Akturk et al., 2016; Bhasin et al., 2018; Lee &
Tillman, 2016; Morales et al., 2015). A client could fall under one category or both,
depending on the circumstances (Akturk et al., 2016; Bhasin et al., 2018; Lee & Tillman,
2016; Morales et al., 2015; Sterling et al., 2015). Either type of hypogonadism may be
labeled congenital or acquired (Akturk et al., 2016; Bhasin et al., 2018; Dwyer et al.,
2019; Lee & Tillman, 2016; Morales et al., 2015; Sterling et al., 2015).
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Figure 3
Diagnosis of Male Hypogonadism

Note. SHBG = sex hormone binding globulin. LH = luteinizing hormone. FSH = follicle
stimulating hormone. From “Male Hypogonadism,” by S. Basaria, 2014, Lancet, 383(1),
p. 1253 (https://doi:10.1016/S0140-6736(13) 61126-5). Copyright 2014 by S. Basaria.

Common symptoms of low testosterone include: decreased sex drive, increased
body fat, erectile dysfunction, complications with memory and/or concentration,
decreased amounts of body hair, increased moodiness and/or irritability, decreased
muscle mass, osteoporosis, decreased sense of well-being, and depression (Anderson et
al., 2016; Aydogan et al., 2012; Cherrier et al., 2015; Dhindsa et al., 2018; Elliott et al.,
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2017; Izzo et al., 2016; Ivanov et al., 2018). Due to the known correlation between a
male’s age increasing and testosterone levels naturally decreasing, the majority of
hypogonadism research focuses on the older male and aging population (Resnick et al.,
2017; Saad et al., 2016; Shin et al., 2016; Snyder et al., 2016; Winters & Huhtaniemi,
2017). One of the primary concerns with hypogonadism is the frequency in which it is
often underdiagnosed or misdiagnosed as another condition (Issacs & Thomas, 2015; Lee
& Tillman, 2016; Silva et al., 2015; Tanriverdi & Kelestimur, 2015).
Secondary Hypogonadism
Secondary hypogonadism, also referred to as hypogonadotropic or central
hypogonadism, reveals that low testosterone is due to a malfunctioning or damaged
hypothalamus or pituitary gland (Barton et al., 2016; Dhindsa et al., 2018; Plessis et al.,
2019). The hypothalamus produces the gonadotropin-releasing hormone, which then
prompts the pituitary gland to produce the follicle-stimulating hormone (FSH) and the
luteinizing hormone (LH) (Aydogan et al., 2012; Bhasin et al., 2010; Morales et al.,
2015). The LH then cues the testes to create testosterone (Morales et al., 2015; Sterling et
al., 2015). Conditions and circumstances that cause secondary hypogonadism include:
genetic defects, severe stress, drug use, long-term medical diseases, or damage to the
hypothalamus or pituitary gland (Bhasin et al., 2018; Dhindsa et al., 2018; Forni & Wray,
2015; Issacs & Geracioti, 2015; Lasaite et al., 2016; McCullough, 2015).
Some of the literature addresses the increasing awareness and connection between
traumatic brain injuries and secondary hypogonadism (e.g. Barton et al., 2016; Issacs &
Thomas, 2015; Izzo et al., 2016; Javed et al., 2015; Reifschneider et al., 2015; Silva et al.,
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2015; Tan et al., 2017; Tanriverdi & Kelestimur, 2015; Tanriverdi et al., 2015; Tritos,
2015). Traumatic brain injuries as Hackenberg and Unterberg (2016) reported, are the
number one cause of long-term disability for young adults. As Silva et al. (2015) and
Tanriverdi et al. (2015) pointed out, hypogonadism following a traumatic brain injury is
more prevalent than previously thought. Izzo et al. (2016) concurred with Silva et al.
(2015) and Tanriverdi et al. (2015) by reporting that hypogonadism occurs in up to half
of all clients who sustain a traumatic brain injury. Barton et al. (2016) and Javed et al.
(2015) also suggested that those with traumatic brain injuries are at a high risk for
developing secondary hypogonadism.
A significant portion of the literature examining secondary hypogonadism covers
the topics of common symptoms and how to properly diagnose (Dhindsa et al., 2018;
Dudek et al., 2017; Sterling et al., 2015; Tarnutzer et al., 2015). Typical symptoms of low
testosterone include changes in sexual functions, sleeping patterns, physical changes, and
emotional changes (Akturk & Nippolt, 2016; Aydogan et al., 2012; Gray et al., 2017;
Huo et al., 2016; Hwang & Miner, 2015; Javed et al., 2015). Within these broader
categories of change, one could see a lower sex drive, irritability, fatigue, body hair loss,
depression, and an overall lower quality of life (Akturk & Nippolt, 2016; Aydogan et al.,
2012; Huo et al., 2016; Hwang & Miner, 2015; Javed et al., 2015). Professionals agree
that when diagnosing hypogonadism, attention must be paid to LH and FSH levels
(Basaria, 2014; Bhasin et al., 2010; Forni & Wray, 2015; Yazdani & Branch, 2018).
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Testosterone Replacement Therapy
The goal of testosterone replacement therapy is to bring the insufficient
testosterone level of the individual back within the designated acceptable range
(Gabrielsen et al., 2016; Khandwala et al., 2018; Layton et al., 2017; Sehn et al., 2018;
Shoskes et al., 2016; Straftis & Gray, 2019). A search through scholarly journals turned
up a variety of articles addressing the history of testosterone replacement therapy
(Anderson et al., 2016; George et al., 2017; Hwang & Miner, 2015; Khandwala et al.,
2018; Lasaite et al., 2016; Sehn et al., 2018; Wynia & Kaminetsky, 2015; Yassin et al.,
2016; Yazdani & Branch, 2018). Research has continued to present an array of materials
that suggest potential beneficial results of testosterone replacement therapy somatically,
sexually, and psychologically speaking (Anaissie et al., 2017; Anderson et al., 2016;
Elliott et al., 2017; Kapoor, 2016; Morales et al., 2015; Ponce et al., 2018; Saad, Aversa,
et al., 2011; Wynia & Kaminetsky, 2015; Yazdani & Branch, 2018).
The current routes of testosterone replacement delivery available include:
transbuccal (through the cheek), oral (through the mouth), intranasal (through the nose),
intramuscular (through the muscle), transdermal (through the skin), and subcutaneous
(through the fat), with the last three considered the primary and most popular options
(Lee & Tillman, 2016; Mintzes, 2018; Spratt et al., 2017; Wynia & Kaminetsky, 2015).
Intramuscular indicates that the testosterone is injected with a needle into a vascular
muscle, typically the deltoid, vastus lateralis, or gluteal regions (Wynia & Kaminetsky,
2015). Transdermal involves a patch, gel, or solution of testosterone being placed on the
surface of the skin (Wynia & Kaminetsky, 2015). Subcutaneous administration includes
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both shots that are injected or pellets that are implanted. Shots or pellets are both
administered into a layer of fat under the surface of the skin (see Figure 4; Spratt et al.,
2017; Wynia & Kaminetsky, 2015).

Figure 4
Subcutaneous Injection of Testosterone

Note. The subcutaneous tissue layer is composed of fatty tissue located directly under the
dermis of the skin. (K. Davis, personal communication, May 14, 2021). Reprinted with
permission (see Appendix A).
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After decades of testosterone replacement therapy research, substantial evidence
has indicated that low levels of testosterone are associated with increased cardiovascular
risks, while higher levels of testosterone are associated with decreased cardiovascular
risks (Alexander et al., 2017; Corona et al., 2016; George et al., 2017; Jasuja et al., 2017;
Jasuja & Rose, 2017; Lunenfeld et al., 2015; Morgentaler et al., 2016; Mullhall et al.,
2018). Of the hundreds of studies, a total of four indicated an increase in cardiovascular
risks; two of these were flawed retrospective studies (Finkle et al., 2014; Vigen et al.,
2013), one was a prospective trial with a few findings (Basaria et al., 2010), and another
one was a meta-analysis that reported results of questionable clinical significance (Xu,
Freeman, Cowling, & Schooling, 2013).
The majority of articles discuss testosterone replacement therapy in older men
(Bhasin et al., 2010; Busnelli et al., 2017; Cherrier et al., 2015; Giuseppe et al., 2020;
Hackett, 2016; Huo et al., 2016; Jung & Shin, 2016; Kim et al., 2016; Konaka et al.,
2016; Lee & Tillman, 2016; McCullough, 2015; Morales et al., 2015; Nian et al., 2016;
Plessis et al., 2019; Saad et al., 2016; Shin et al., 2016; Snyder et al., 2018). Huo et al.
(2016) performed a systematic review of 156 journal articles, with the focus on
testosterone replacement therapy for older individuals with cardiovascular disease. The
results of the studies appeared to be inconsistent; some reported the clinical effects
favoring testosterone therapy, while others reported the clinical effects favoring the
placebo (Huo et al., 2016; Mullhall et al., 2018). Looking specifically at the treatment of
testosterone replacement therapy for depression, Huo et al. (2016) also reported
inconsistent and mixed findings. In alignment with the findings of Huo et al, Ponce et al.
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(2018) reported that the safety and efficacy of testosterone replacement therapy in men
with hypogonadism continues to remain insufficiently understood.
Ponce et al. (2018) and Yassin et al. (2016) looked at some of the physiological
effects of long-term testosterone replacement therapy, primarily erectile functioning,
body weight, and metabolic parameters. According to the majority of researchers,
testosterone replacement therapy is effective for increasing erectile functions and bone
mineral density, while decreasing fat mass (George et al., 2017; Morgentaler et al., 2016;
Ponce et al., 2018).
The Morgentaler et al. (2016) article stood out; it was written by members of a
panel of international experts comprised of urologists, endocrinologists, internal medicine
specialists, and scientific researchers. The conference of experts represented 4 continents
and 11 countries (Morgentaler et al., 2016). The panel discussed hypogonadism and
testosterone replacement therapy, and came to a unanimous conclusion on nine key
points advocating: (a) hypogonadism is a concern on a global scale, (b) there is no
scientific basis for any type of age-related suggestions against utilizing testosterone
replacement therapy in men, (c) there is a lack of evidence to support increased
cardiovascular risk or prostate cancer, and (d) testosterone replacement therapy for males
with hypogonadism is effective and evidence-based (Morgentaler et al., 2016).
How Testosterone Replacement Therapy Affects Depression
When analyzing the results of scholarly studies, inconsistencies appeared; some
researchers reported that testosterone replacement therapy has an effect on levels of
depression, while others reported the opposite (Aydogan et al., 2012; Basaria, 2014;
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Bhasin et al., 2010; Cherrier et al., 2016; Hwang & Miner, 2015; Jung & Shin, 2016;
Lasaite et al., 2016; Lee & Tillman, 2016; Morales et al., 2015; Ponce et al., 2018; Shin
et al., 2016; Snyder, 2016). Aydogan et al. (2012), Basaria (2014), Cherrier et al. (2015),
Lasaite et al. (2016), Lee and Tillman (2016), and Snyder et al. (2016) found testosterone
replacement therapy as having varying degrees of efficacy on levels of depression.
Cherrier et al. and Lasaite et al. were the only researchers to describe the effects of
testosterone replacement therapy on depression as significant and substantial. Aydogan et
al., Basaria et al., and Lee and Tillman, reported observable improvements in levels of
depression, post testosterone therapy treatments. Snyder reported small-to-moderate
degrees of improvements with measuring levels of depression, when testosterone therapy
treatments increased from a moderate/low range to a mid/normal range. Bhasin et al.,
Huo et al., (2016) and Jung and Shin reported inconsistent effects of testosterone
replacement therapy on depression.
Only a handful of the scholarly literature returned results analyzing males under
the age of 50 (Aydogan et al., 2012; Huo et al., 2016; Lasaite et al., 2016). Aydogan et al.
(2012) acknowledged depression as being one of the most common psychopathological
conditions in young males with hypogonadism. The Aydogan et al. study analyzed 40
males with congenital secondary hypogonadism whose average age was 23.42. The
findings indicated that males with lower levels of testosterone might display increased
negative psychological symptoms like depression (Aydogan et al., 2012). Huo et al.
(2016) performed a systematic review of 156 papers spanning 65+ years of research; a
small number of those papers analyzed males under the age of 50, or whose mean age
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was under 50. Huo et al. reported for those males, inconsistent findings when treating
depression with testosterone replacement therapy. Lasaite et al. (2016) looked at young
and middle-aged males with hypogonadism, whose mean age was 30.5. Lasaite et al.
indicated that testosterone replacement therapy appeared to have a beneficial effect on
depression scores.
How Testosterone Replacement Therapy Affects Quality of Life
The results of the literature appear to be inconsistent; some researchers reported
testosterone replacement therapy as effecting quality of life positively, while others
reported the opposite (Aydogan et al., 2012; Basaria, 2014; Bhasin, 2010; Konaka et al.,
2016; Lasaite et al., 2016; Morales et al., 2015; Morgentaler et al., 2016; Nian et al.,
2017; Ponce et al., 2018; Shiraishi et al., 2014). Aydogan et al. (2012), Bhasin et al.
(2010), Morgentaler et al. (2016), and Shiraishi et al. (2014) found general improvements
in the quality of life scores following testosterone replacement therapy. Cherrier et al.
(2015), Huo et al. (2016), and Lasaite et al. (2016), indicated that they found no
significant changes or beneficial effects of testosterone replacement therapy on quality of
life scores. Basaria (2014) took neutral ground reporting the role of testosterone
replacement therapy on quality of life remains unclear due to the results of the various
trials conflicting with one another.
Only a handful of the scholarly literature reported results after studying males
under the age of 50 (Aydogan et al., 2012; Huo et al., 2016; Lasaite et al., 2016; and
Shiraishi et al., 2014). Aydogan et al. (2012), who reported observable improvements in
the quality of life scores, analyzed 40 males with congenital secondary hypogonadism,
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whose average age was 23.42. Huo et al. (2016) utilized a handful of papers stemming
from a systematic review that analyzed males under the age of 50, or whose mean age
was under 50. Huo et al. reported testosterone replacement therapy as having no effect on
an individual’s quality of life. Lasaite et al. (2016) indicated no beneficial effects in an
individual’s quality of life. Lasaite et al. also disclosed the full effects of testosterone
replacement therapy for young, hypogonadal, adult males have yet to be fully evaluated.
Shiraishi et al. (2014) analyzed hypogonadal males whose Mean was 26.1. Shiraishi et al.
associated testosterone replacement therapy with significant improvements for those with
secondary hypogonadism.
Summary
In this chapter, I provided an exhaustive review of the literature on the research
topic of psychological effects of testosterone replacement therapy for males under the age
of 50, with secondary hypogonadism. I also introduced a detailed analysis of the
biopsychosocial model as the theoretical framework was also explored within this chapter
and how it connected to the biomedical variable of time exposed to testosterone
replacement therapy with the psychosocial variables of depression and quality of life. In
this chapter, I provided the key variables and concepts of hypogonadism, secondary
hypogonadism, and testosterone replacement therapy. I also discussed major themes
present in the literature including how testosterone replacement therapy affects
depression and quality of life. In this chapter, I provided a summary of what is well
known versus what is not known in relation to the topic of testosterone replacement
therapy for males under the age of 50 with secondary hypogonadism. I also explored the
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inconsistencies and gaps in the literature surrounding how testosterone replacement
therapy affects or does not affect levels of depression and the quality of life. In this
chapter I also offered an explanation for extending knowledge of medical concerns that
present as psychological symptoms into the field of clinical psychology. In Chapter 3, I
provide detailed descriptions and justifications for the selected research methods utilized
in the current study.
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Chapter 3: Research Methodology
Introduction
The purpose of this quantitative study was to investigate the psychological effects
of testosterone replacement therapy for males under the age of 50 with secondary
hypogonadism over a 2-month period. The independent variable was time exposed to
testosterone replacement therapy, while the dependent variables were quality of life and
depression. The patients in this study were required to have a diagnosis of low
testosterone and have a recommendation of testosterone replacement therapy from their
medical doctor. I gathered all data for this study from an existing, archived data set. No
direct communication occurred between myself and the patients.
In Chapter 3, I describe the research methodology that I used in this study. A brief
review of the design and rationale of the study, including the setting and sampling
procedures; procedures for recruitment, participation and data collection; and
instrumentation, is also presented. The data analysis plan is explored, including RQs,
hypotheses, and statistical tests. Additionally, threats to external, internal, and construct
validity, including reliability of the instrument, data assumptions, sample size, and the
measures taken to protect the rights of the participants are presented. Finally, I describe
ethical procedures and concerns related to this study.
Research Design and Rationale
I conducted this study using a quantitative, non-experimental design. According
to Creswell (2014), a quantitative approach offers researchers a chance to work with data
from various sample sizes and generalize about larger populations. Creswell suggested a
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quantitative design is a sufficient approach when determining if a relationship exists
between variables or when evaluating various theories. The primary goal of this
nonexperimental design was to determine whether or not a relationship existed between
the independent variable and the dependent variables.
I analyzed the association between time exposed to testosterone replacement
therapy, and the psychological constructs of quality of life and depression. To accomplish
this goal, data were gathered from a health clinic and then quantitatively analyzed. I used
secondary data, which means the variables were not manipulated or controlled in any way
(Creswell, 2014). A sample was drawn from the medical records. Data were then
assessed in order to determine whether a relationship existed between time exposed to
testosterone replacement therapy and the participants’ self-rated scores on depression and
quality of life.
Repeated measures (r) is a research design sometimes paired with an analysis of
variance (ANOVA), which is a statistical tool. An rANOVA is a statistical method used
by researchers to analyze the equality of means across variables that are fabricated with
repeated observation (Creswell, 2014; Guo et al., 2013; Morgan et al., 2012). More
specifically, I used a one-way rANOVA meaning there was only one independent
variable, also known as the within-subjects factor. One of the advantages of using a oneway rANOVA is that it allows for the use of the participants as their own control which
decreases variability (Creswell, 2014; Guo et al., 2013; Morgan et al., 2012). The
repeated measure design makes it possible to account for the differences and separate
them from the treatment and error conditions (Creswell, 2014; Guo et al., 2013; Morgan
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et al., 2012). Collecting repeated measurements of variables is also an advantage because
it supplies a more definitive assessment of how change occurs within each person over a
specific duration of time (Guo et al., 2013; Morgan et al., 2012). The intent and purpose
of using a one-way rANOVA was to evaluate and see how each of the two dependent
variables (quality of life and depression) were affected by the independent variable (time
exposed to the testosterone replacement therapy). The independent variable was
measured at baseline, 1 month, and 2 months.
Methodology
Population
The target population for this study was males under the age of 50 who were
diagnosed with secondary hypogonadism. I collected secondary data from a health clinic
on the East Coast of the United States. The clinic already gathers relevant data relating to
the dependent variables of this study (depression and quality of life). The participants in
this study were males under the age of 50 who were receiving testosterone replacement
therapy for low testosterone in Spring 2021. The general population of individuals with
secondary hypogonadism in the United States is estimated to be somewhere between two
and four million (Barton et al., 2016; Hohl et al., 2014; Sterling et al., 2015).
Sampling and Sampling Procedures
I used purposive sampling for this study because this particular health clinic
collects specific information relevant to this study (specific to out-patient individuals
using testosterone replacement therapy), while measuring various symptomatic
descriptors. I chose to use this nonprobability technique based on characteristics of the
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health clinic (population) and testosterone replacement therapy. Purposive sampling was
suitable for this study’s variables and RQs, which centered on determining the extent of
the relationship between length of exposure to testosterone replacement therapy and
depression and quality of life in males under the age of 50 with secondary hypogonadism
over a 2-month period.
I analyzed secondary data collected in the Spring of 2021, by a health clinic on
the East Coast of the United States. The procedure for gathering the sample involved
several measures. First, all participants whose data was analyzed from the clinic received
testosterone replacement therapy by subcutaneous injections of testosterone cypionate,
USP, which is the oil-soluble 17 (beta)–cyclopentylpropionate ester of the androgenic
hormone testosterone (Borodi et al., 2020; Meng et al., 2015; Shoskes et al., 2016;
Vogiatzi et al., 2021). The chemical composition of testosterone cypionate, USP is
adrost-4-en-3-one, 17-(3-cyclopentyl-1-oxopropoxy)-,(17b)- (Borodi et al., 2020; Meng
et al., 2015; Shoskes et al., 2016; Vogiatzi et al., 2021). Each milliliter (mL) of the 200
mg/mL formula includes testosterone cypionate, USP 200 mg, benzyl benzoate, USP
0.25 mL, benzyl alcohol, USP 0.02 mL, and grapeseed oil 0.50 mL (Borodi et al., 2020;
Meng et al., 2015; Shoskes et al., 2016; Vogiatzi et al., 2021). Second, the deidentified
patient records were provided and included age (history forms), quality of life
measurement (questionnaire), depression measurement (questionnaire), the start date of
the testosterone replacement therapy (lab results), and testosterone levels measured with a
total-testosterone test (lab results). Patients receiving testosterone replacement therapy for
primary hypogonadism (hypergonadotropic hypogonadism/testicular failure) were
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excluded from the study. All information gathered for this study came from the secondary
data meaning there was no direct contact or communication between myself and the
patients. The clinic involved with this study is the legal owner of their respective data.
Agreements between myself and the provider of the data ensured protection and
confidentiality of patient information.
The sample size of a study is typically determined before research begins in order
to make sure an adequate number of responses are gathered (Creswell, 2014; Guo et al.,
2013). Having a sufficient and adequate sample size ensures that enough data have been
gathered to make inferences about a given population (Creswell, 2014; Guo et al., 2013).
Selecting an appropriate sample size for studies that utilize repeated measures is crucial
when calculating a successful study (Creswell, 2014; Guo et al., 2013). I used G*Power
3.1.9.7 (Faul et al., 2009) with Cohen’s f test was used to calculate the sample size for a
one-way repeated measures analysis of variance (rANOVA).
Cohen (1982) stated that when a population is limited in size, it is appropriate to
set the alpha at .10 or higher. Faul et al. (2009) suggested that the lowest acceptable priori
power is .70. With the correlation among repeated measures set at .50, an alpha level of
.05, power set at .80, and a confidence level of 95%, an effect size of .40 would be
detectable with a sample size of 12. Although the recommended sample size was 12, I
drew a larger sample to help decide whether a statistically significant effect existed
between the independent and dependent variables. I also used a large effect size to align
with various researchers who reported that the impact of testosterone replacement therapy
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on various psychological factors was significant or large (Jung & Shin, 2016; Saad, et al.,
2011; Zweifel & O’Brien, 1997).
Archival Data
I analyzed secondary data collected in the Spring of 2021, by a health clinic on
the East Coast of the United States. At the beginning of the research project process, I
made contact with one of the owners of the clinic. The study was introduced, explained,
and a request was made to utilize the archival data. Approval was given by the clinic to
obtain patient’s pertinent records for this study. The procedure for gaining access to the
data set involved a data use agreement between the data provider (health clinic) and the
data recipient (me). The agreement allowed for limited use of deidentified information
for the singular purpose of research. The data use agreement with the health clinic,
allowed specified access to a limited, deidentified data set (age, quality of life
measurement, depression measurement, the start date of the testosterone replacement
therapy, and testosterone levels measured with a total-testosterone test). The health clinic
maintained the sole rights to all records needed for this study; therefore, client permission
was not required or necessary. Patients were identified by an identification number (118), and remained confidential in order to protect all information shared for this study. I
input the data into SPSS Version 27 for statistical analysis (Morgan et al., 2012).
Instrumentation and Operationalization of Constructs
Patient Health Questionnaire – 9
I administered the PHQ-9, which is used to operationalize, diagnose, monitor, and
measure perceived levels of depression in patients (Chen et al, 2016; Manea et al., 2015;
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Mitchell, et al., 2016). Comprised of nine questions, the PHQ-9 is an interval scale, selfadministered instrument that incorporates DSM-5 depression diagnostic criteria (APA,
2013; Munoz-Navarro et al., 2017). The PHQ-9 is an assessment specifically designed to
measure levels of depression (Chen et al, 2016; Keum et al., 2018; Munoz-Navarro et al.,
2017). The PHQ-9 was developed thanks to an educational grant provided by Pfizer
(Kroenke et al., 2001). Permission to use the instrument is not necessary because it is in
the public domain.
As Kroenke et al. (2001) pointed out, the PHQ-9 can be repeatedly administered
to reflect improvement or worsening of depression in response to treatment. The
diagnostic validity of the PHQ-9 was established in various studies involving eight
primary care clinics and seven obstetrical clinics (Kroenke et al., 2001). The nine
questions specifically refer to the past 2 weeks of a patient’s life and how often they have
been bothered by problems including: having minimal interest or pleasure in doing
things; feeling down, depressed, or hopeless; trouble falling asleep, staying asleep, or
sleeping too much; feeling tired or having little energy; having poor appetite or
overeating; feeling bad about one’s self or that one is a failure or has let one’s self or
one’s family down; difficulty concentrating on things; moving or speaking so slowly that
other people could have noticed; being fidgety or restless; moving around a lot more than
usual; and thoughts that one would be better off dead or hurting one’s self in some way
(Kroenke et al., 2001; Mitchell et al., 2016).
The nine questions cover specific depression diagnostic criteria of the DSM-5 and
have three main scoring formats: PHQ-9-linear, PHQ-9-algorithm, and PHQ-2 (APA,
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2013; Mitchell et al., 2016). I used the PHQ-9-linear, which is scored with simple
addition, and has a sensitivity and specificity of 88% for detecting major depressive
disorder (Mitchell et al., 2016). The scoring used a Likert system with four choices that
include not at all, several days, more than half the days, or nearly every day (Kroenke et
al., 2001).
PHQ-9 scores range from 0–27; the higher the number, the more depressed an
individual feels (Kroenke et al., 2001). A score of 0-4 gives a provisional diagnosis of
minimal depression (Kroenke et al., 2001). A score of 5-9 gives a provisional diagnosis
of mild depression (Kroenke et al., 2001). A score of 10-14 gives a provisional diagnosis
of moderate depression (Kroenke et al., 2001). A score of 15-19 gives a provisional
diagnosis of moderately severe depression (Kroenke et al., 2001). A score of 20-27 gives
a provisional diagnosis of severe depression (Kroenke et al., 2001).
Recent studies indicate that the PHQ-9 is a highly reliable and valid instrument
that can be used for screening and measuring depression with a wide variety of
populations (Chen et al., 2016; Gelaye et al., 2016; Manea et al., 2015; Mitchell et al.,
2016; Munoz-Navarro et al., 2017). Chen et al (2016) used over 600 participants to assess
the reliability, validity, and factor structure of the PHQ-9. The results of Chen et al
indicated internal consistency (α = 0.77), test/retest reliability (0.79), and concurrent
validity (r = 0.66; p < 0.001). Gelaye et al (2016) used almost 1,000 participants to assess
the reliability and validity of the PHQ-2, which is one of two subscales of the PHQ-9.
The results of Gelaye et al indicated strong construct and criterion validity, which makes
the assessment tool attractive and preferred as an extremely brief screening questionnaire.
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Manea et al (2015) performed a bivariate meta-analysis of different scoring methods of
the PHQ-9. Manea et al indicated that the algorithm method, which tends to miss a
significant number of patients with major depressive disorder, leads to low sensitivity
(0.55). Manea et al also indicated that the linear standard cut-off method leads to a more
acceptable sensitivity (0.77) and maintained a strong specificity (0.85). Mitchell et al
(2016) performed a meta-analysis of 40 individual studies and reported sensitivity and
specificity for detecting major depressive disorder with the PHQ-9 at 88%. MunozNavarro et al (2017) used 178 patients to obtain optimal cut-off values for screening and
identifying those suspected to have major depressive disorder. Munoz-Navarro et al
indicated an optimal cut-off value of 12 rather than 10, which is the most commonly used
cut-off value. Appendix C includes the PHQ-9 in its entirety.
Quality of Life Scale
I also used the QoLS (Burckhardt & Anderson, 2003) to operationalize and
measure quality of life in patients. Comprised of 16 items, the QoLS is an interval scale,
self-administered instrument that analyzes the quality of life concept (Burckhardt &
Anderson, 2003). The QoLS was developed in the 1970s by John Flanagan (Burckhardt
& Anderson, 2003; Gupta & Venkatesan, 2018). Permission to use this instrument is not
necessary because it is in the public domain.
As Burckhardt and Anderson (2003) pointed out, the reliability, content, and
construct validity of the QoLS have been demonstrated in a number of studies.
Burckhardt and Anderson also indicate that the QoLS has correlations with physical
health standings and disease impact measures that fall between the low and moderate
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ranges. Burckhardt and Anderson also highlighted that content validity analysis indicates
that the tool accurately measures domains that a wide variety of patient groups define as
quality of life. The QoLS is regarded as a valid and reliable instrument for measuring
quality of life across various groups and cultures and is conceptually unlike other
indicators of quality of life (Burckhardt & Anderson, 2003; Cooke et al., 2016;
Dronavalli & Thompson, 2015; Hagg et al., 2003; Uddin et al., 2017).
United States established diagnostic validity in the 1970s with the QoLS using a
random sampling of 3,000 adults (Burckhardt & Anderson, 2003). The original scale
included 15 items that incorporated five conceptual realms of quality of life (Burckhardt
& Anderson, 2003). The five realms cover material and physical well-being; relationships
with others; social, community, and civic activities; personal development and
fulfillment; and recreation.
In the early 1980s, qualitative research explored individuals with chronic illnesses
and their perceptions of quality of life (Burckhardt & Anderson, 2003). After those
findings, the QoLS was increased to include one more realm, Independence, or the
capability of an individual to do for him or herself (Burckhardt & Anderson, 2003). The
QoLS presently consists of 16 items: material comforts, home, food, conveniences, and
financial security; health; relationships with parents, siblings and other relatives; having
and rearing children; close relationships with spouse or significant other; close friends;
helping and encouraging others, volunteering, and giving advice; participating in
organizations and public affairs; learning; understanding yourself; work; expressing
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yourself creatively; socializing; reading, listening to music, and observing entertainment;
participating in active recreation; and independence.
The 16 items are scored utilizing a Likert system with seven choices that include:
delighted, pleased, mostly satisfied, mixed, mostly dissatisfied, unhappy, and terrible
(Burckhardt & Anderson, 2003). The QoLS has internal consistency (α = .82 to .92) as
well as high test-retest reliability in individuals who have been diagnosed with chronic
illnesses (r = 0.78 to r = 0 .84) (Burckhardt & Anderson, 2003). Studies indicate that the
QoLS is a highly satisfactory instrument that can be utilized for measuring quality of life
with a wide variety of populations (Burckhardt & Anderson, 2003; Hägg et al., 2003).
QoLS scores range from 16-112, the higher the number, the more satisfied an individual
feels (Burckhardt & Anderson, 2003). Average scores for a healthy population are
approximately 90 (Burckhardt & Anderson, 2003). Scores for populations with health
concerns like post-traumatic stress disorder, psoriasis, or chronic obstructive pulmonary
disease, tend to average closer to 80 (Burckhardt & Anderson, 2003). Appendix C
includes the QoLS in its entirety.
Data Analysis Plan
I used SPSS Version 27 to analyze the archived depression and quality of life
scores of the individuals participating in the current study. The collected data were
visually inspected and then SPSS was utilized to address each of the RQs and hypotheses
with a one-way rANOVA. Constructing the one-way rANOVA involved measuring and
determining the extent of the relationship in which time exposed to testosterone
replacement therapy (independent variable) effected depression and the quality of life
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(dependent variables). The independent variable was measured at three equal intervals of
time. Any participant who did not visit the clinic for all three visits had their information
removed from the final analysis. The first measurable period was the baseline or the first
time point in which the participants were measured. Participants were not yet exposed to
testosterone replacement therapy at the first interval. The second measurable period was
month one into the testosterone replacement therapy treatment. Participants had been on
testosterone replacement therapy for one month at that point. The third measurable period
was two months into the testosterone replacement therapy treatment. This was the final
time point in which the participants were measured.
Restatement of the Research Questions and Hypotheses
RQ1: Is the psychological aspect of quality of life significantly affected by
testosterone replacement therapy maturation?
H01: The mean scores for the psychological aspect of quality of life, as assessed
by the QoLS, do not differ significantly over baseline, 1 month, and 2 months of
testosterone replacement therapy maturation, in males under the age of 50
suffering from secondary hypogonadism.
Ha1: The mean scores for the psychological aspect of quality of life, as assessed
by the QoLS, do differ significantly over baseline, 1 month, and 2 months of
testosterone replacement therapy maturation, in males under the age of 50
suffering from secondary hypogonadism.
RQ2: Is the psychological aspect of depression significantly affected by
testosterone replacement therapy maturation?
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H02: The mean scores for the psychological aspect of depression, as assessed by
the PHQ-9, do not differ significantly over baseline, 1 month, and 2 months of
testosterone replacement therapy maturation, in males under the age of 50
suffering from secondary hypogonadism.
Ha2: The mean scores for the psychological aspect of depression, as assessed by
the PHQ-9, do differ significantly over baseline, 1 month, and 2 months of
testosterone replacement therapy maturation, in males under the age of 50
suffering from secondary hypogonadism.
Assumptions for rANOVAs
Initially, a preliminary exploratory data analysis was conducted to determine if
the data met the assumptions of rANOVA, primarily normality and sphericity, and
whether or not it was free of outlier scores. When data are analyzed utilizing a one-way
rANOVA there are five assumptions to be considered (Verma, 2015). Assumption 1, at
least one of the dependent variables must be continuous (Verma, 2015). In this study,
both dependent variables (quality of life and depression) were considered continuous
(Bowins, 2015; Hankin et al., 2005; Verma, 2015). Assumption 2, the within-subjects
factor is considered categorical with at least three levels (Verma, 2015). The withinsubjects factor in this study was the independent variable (time exposed to testosterone
replacement therapy), which was measured at three different points of time (baseline, 1
month, and 2 months). If either of the first two assumptions would have been violated, an
rANOVA would not be the best fit for statistical analysis.
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Assumption 3, significant outliers should not exist in any of the levels (Girden,
1991; Verma, 2015). No data points within this study strayed from the typical pattern.
Assumption 4, the dependent variables (quality of life and depression) should be within
the vicinity of a normal distribution at each measurement (level of the within-subjects
factor) (Verma, 2015). Assumption 5, an equality of variance exists between all
amalgamations of levels of the within-subjects factor (also known as sphericity) (Verma,
2015). Sphericity is defined as a primary and crucial assumption of rANOVAs (Field,
2018). Sphericity occurs when one looks at all possible pair combinations of the withinsubject conditions and sees that the variances are equal (Field, 2018).
The last three assumptions correlate to the inherent nature of the data and are
easily examinable utilizing statistical software like SPSS (Verma, 2015; Weinfurt, 2000).
Statisticians indicate it not unusual for the collected data to violate one, two, or all three
of these final assumptions (Verma, 2015; Weinfurt, 2000). Appropriate actions that could
be considered if one or more of the last three assumptions were violated include:
correcting the data so it would not fail the assumptions, utilizing a different statistical
test, or carrying on with the analysis even though the data fails specific assumptions
(Verma, 2015; Weinfurt, 2000).
When violations occur with assumption three, the researcher must decide whether
or not to keep the outliers (Bowins, 2015; Hankin et al., 2005; Verma, 2015). The
concern with outliers is they can negatively affect the rANOVA by causing distortion
differences between the within-subjects factor levels, and cause issues with
generalizability (Bowins, 2015; Hankin et al., 2005; Verma, 2015). When violations
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occur with assumption four (normality), some leeway is given due to robustness (Verma,
2015). Some violations of normality are acceptable and even then the rANOVA can still
provide valid results (Bowins, 2015; Hankin et al., 2005; Verma, 2015). Methods such as
the Shapiro-Wilk test for normality are common procedures to test the assumption of
normality (Bowins, 2015; Hankin et al., 2005; Verma, 2015). When violations occur with
assumption five it can lead to elevated Type I errors, meaning discovering a statistically
significant result when one does not exist (Verma, 2015). Tests such as Mauchly’s test of
sphericity can assist in determining whether or not data has violated the final assumption
(Verma, 2015; Weinfurt, 2000).
Threats to Validity
External Validity (Generalizability)
External validity is the extent in which the results of this study are generalizable
to other individuals and circumstances (Frankfort-Nachmias et al., 2015). Repeated
measures do not typically impact external validity (Frankfort-Nachmias et al., 2015). The
results of this study might not be generalizable due to the intended population and the
limitation of the data collection. Data were analyzed from a regional facility which
represent an unknown percentage of individuals with secondary hypogonadism who
made the decision to visit a health clinic. Other individuals exist with secondary
hypogonadism that are unaware the condition, or may be aware of the condition but may
seek treatment from other facilities and professionals including religious leaders or
naturopathic physicians.
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It is also important to recognize that accessibility plays a role in determining
which individuals made the decision to visit the health clinic utilized in this study.
Physical, economic, and social dimensions are also factors that contributed to whether or
not an individual made the decision to visit the health clinic used in the current study. A
one-way rANOVA was used with this study to allow both dependent variables
(depression and quality of life) to be measured with the same independent variable (time
exposed to testosterone replacement therapy). I used a within-subject variable of interest
(effect over time) to determine if the patients felt a difference from the first measurement
(baseline) to the final measurement (2 months from baseline).
Internal Validity
Internal validity is the extent in which the effects of the study are due to the
manipulation of the independent variable and not something else (Creswell, 2014;
Frankfort-Nachmias et al., 2015). I used a one-way rANOVA to determine the impact
that time exposed to testosterone replacement therapy has on depression and quality of
life (Creswell, 2014; Frankfort-Nachmias et al., 2015). Threats to internal validity include
the following biases which could be present in the population being studied: (a) selfreport response bias, or the tendency for an participant to provide more positive or
negative responses to questions; (b) selection–history bias, where participants being
administered testosterone replacement therapy might differ from one another; (c)
selection–maturation, where participants may have previous exposure to various types of
testosterone replacement therapy methods compared to others who have not; (d)
confounding variables, like the within-subjects designs test that measures the same
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participants each time. Any number of circumstances or situations could have happened
to any of the participants between measuring periods, like missing one or more doses
(Creswell, 2014; Frankfort-Nachmias et al., 2015). Potential effects the subjects of this
study reported include increases, decreases, or no noticeable changes to their quality of
life or perceived levels of depression.
Ethical Procedures
Ethical behaviors and protection for all participating clients and information are a
serious matter for those who conduct psychological studies. Every action in this study
was taken with careful consideration in mind for the participants. Agreement to gain
access to the data was received by way of a formal Data Use Agreement. The agreement
was signed by both the data provider and the data recipient to allow the usage of the
deidentified data set from the participating health clinic. The data were anonymous and
the agreement was limited to the client’s age, quality of life measurement, depression
measurement, dates of the testosterone replacement therapy injections, and testosterone
levels measured with a total-testosterone test.
This study did not involve any interactions with or observations of human
participants. Permission to conduct this study was awarded from the Committee on
Ethical Standards in Research from Walden University’s Institutional Review Board
(IRB) by completing an application to ensure that the ethical principles of beneficence
and nonmaleficence, fidelity and responsibility, integrity, justice, and respect for people’s
rights and dignity were upheld during this study. The IRB granted final approval in
February 2021; the approval number for this study is 02-19-21-0559221.
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I used secondary data, limiting the ethical concerns related to recruitment
materials, processes, and data collection. In the collection of the original data, it is hoped
the initial collectors of the data were able to ensure that the participants were treated
fairly. It is also assumed the original collectors ensured that limits of confidentiality were
discussed and guaranteed during the initial data collection process.
The data were stored safely and securely during this entire process. In compliance
with the State of Ohio guidelines, all data will be held for a minimum of seven years. The
electronic copies of data that were received from the data provider are stored on a laptop
with three levels of security and will require gained access entry.
I input the raw data into SPSS Version 27 for statistical analysis, using my
personally secured, administrator password-protected laptop, equipped with antivirus,
anti-spyware, and added Alexa protection. Following analysis, statistical data were then
securely stored on a separate hard drive with restricted access by administrator password
protection. Write permission was also disabled to ensure an additional security measure,
preventing altercations of the data. The data will be kept for seven years as required by
the state of Ohio and the American Psychological Association, which also fulfills Walden
University’s guidelines stating data must be kept for a minimum of five years. Copies are
stored in two different locations. After seven years, the data will be securely disposed of
and erased from the laptop. Secondary data allow for additional protections to both the
population and myself.
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Summary
In this chapter, I offered explanations and justifications behind the research
methods employed in this study. A brief review and rationale of the study and reveals a
repeated measures design is suitable due to the comparisons of the same subjects under
different conditions. In this chapter I also described the target population, the health
clinic setting, and the purposive sampling procedure. I discussed the utilization of
secondary data analysis and presented the procedures involved for recruitment,
participation and data collection. In this chapter, I covered details involving the
instrumentation and operationalization of constructs specifically for the PHQ-9 and the
QoLS. I also explored the data analysis plan through SPSS including the two RQs and the
four hypotheses. In addition, I provided justification for threats to external and internal
validity, including reliability of the instrument, data assumptions, sample size, and the
measures taken to protect the rights of the participants. Finally, I provided a detailed
description of the ethical procedures including the Data Use Agreement and concerns that
came up with Walden University’s IRB board. In Chapter 4, I offer detailed descriptions
and justifications for the results.

56
Chapter 4: Results
Introduction
The purpose of this study was to investigate the psychological effects of
testosterone replacement therapy for males under the age of 50 with secondary
hypogonadism. I wanted to determine if a relationship existed between time exposed to
testosterone replacement therapy and depression and quality of life among males under
the age of 50 who had been diagnosed with secondary hypogonadism. In Chapters 1 and
2, I conveyed evidence of a gap in the literature while in Chapter 3, I provided an
overview of the research method for the study. A rANOVA was used as the statistical
tool for the dependent variables, which were depression and quality of life.
I begin this chapter by reviewing the RQs and hypotheses. Also discussed is the
time frame for data collection, the response rates, basic demographic characteristics of
the sample, statistical results, and a summary of the findings. I designed the study to
explore the following RQs through evaluation of the corresponding hypotheses.
RQ1: Is the psychological aspect of quality of life significantly affected by
testosterone replacement therapy maturation?
H01: The mean scores for the psychological aspect of quality of life, as assessed
by the QoLS, do not differ significantly over baseline, 1 month, and 2 months of
testosterone replacement therapy maturation, in males under the age of 50
suffering from secondary hypogonadism.
Ha1: The mean scores for the psychological aspect of quality of life, as assessed
by the QoLS, do differ significantly over baseline, 1 month, and 2 months of
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testosterone replacement therapy maturation, in males under the age of 50
suffering from secondary hypogonadism.
RQ2: Is the psychological aspect of depression significantly affected by
testosterone replacement therapy maturation?
H02: The mean scores for the psychological aspect of depression, as assessed by
the PHQ-9, do not differ significantly over baseline, 1 month, and 2 months of
testosterone replacement therapy maturation, in males under the age of 50
suffering from secondary hypogonadism.
Ha2: The mean scores for the psychological aspect of depression, as assessed by
the PHQ-9, do differ significantly over baseline, 1 month, and 2 months of
testosterone replacement therapy maturation, in males under the age of 50
suffering from secondary hypogonadism.
Data Collection
Walden University’s Institutional Review Board (IRB) awarded approval (no. 0219-21-0559221) in February 2021 to collect and analyze secondary data provided by a
health clinic on the East Coast of the United States. The time frame for data collection
was Spring 2021. The health clinic I partnered with sent, via email, pertinent information
to me for 18 de-identified individuals, whose demographics met the required qualifying
criteria (male, under the age of 50, receiving testosterone replacement therapy for
secondary hypogonadism). I uploaded the de-identified information into SPSS Version
27 for data analysis. Of the 18 cases, 17 included all necessary points of data (baseline, 4weeks, and 8-weeks) to be analyzed during the study. One of the individuals was missing
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data for the Week-4 input, meaning that utilizing that particular individual’s incomplete
data was not acceptable. See Table 1 for a summary of the cases included and excluded
from analysis.
Table 1
Case Processing Summary for Dependent Variables

N

Valid
%

Cases
Missing
N
%

N

Total
%

Dependent
variable
Depression

17

94.4

1

5.6

18

100.0

Quality of life

17

94.4

1

5.6

18

100.0

The purposive sample (N = 17) was comprised of males under the age of 50,
receiving testosterone replacement therapy for secondary hypogonadism. I used
purposive sampling for this study because this particular health clinic collects specific
information relevant to my study (specific to out-patient individuals using testosterone
replacement therapy), while measuring various symptomatic descriptors. The primary
objective of a purposive sample is to create a sample that is reasonably presumed to be
representative of the population (Etikan et al., 2016). Purposive sampling means that the
subset creates a sample that can be considered logically accurate, reflecting and aligning
with the characteristics of the population for the purposes of analysis (Etikan et al.,
2016).
Because I was interested in analyzing males under the age of 50 with low levels
of testosterone, I made sure that the sample reflected those particular qualities (see Etikan
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et al., 2016). The two dependent variables (depression and quality of life) were analyzed
and measured in relation to the independent variable. The independent variable (time
exposed to testosterone replacement therapy) consisted of three points in time, which
included baseline (before the testosterone replacement therapy began), 1 month into
treatment, and 2 months into treatment.
Results
Measures of Depression
I conducted a one-way rANOVA to determine whether there were statistically
significant differences in levels of depression over the course of a 2-month exposure to
testosterone replacement therapy. Table 2 shows the descriptive statistics for the
dependent variable, depression. There were no outliers and the data were normally
distributed, as assessed by a boxplot and a Shapiro-Wilk test (p > .05). The assumption of
sphericity was not violated, as assessed by Mauchly’s test of sphericity, χ2(2) = 4.32, p =
.115.
Some statisticians consider Mauchly’s test a substandard procedure to expose
violations of sphericity with it often failing to detect deviations from sphericity in smaller
sample sizes (Kesselman et al., 1980; Maxwell & Delaney, 2004; Weinfurt, 2000).
Maxwell and Delaney (2004) recommended that the unadjusted test should be avoided
due to the extreme sensitivity of the one-way rANOVA to departures from sphericity.
Instead, they recommended disregarding the result of Mauchly’s sphericity test and
utilizing the result of the Greenhouse-Geisser correction (Maxwell & Delaney, 2004).
Therefore, a Greenhouse-Geisser correction was implemented (ε = 0.800). The
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testosterone replacement therapy elicited statistically significant changes in levels of
depression over an 8-week period of time, F(1.60, 25.60) = 86.55, p < .001, partial η2 =
.84, partial ω2 = .76, with levels of depression decreasing from baseline (M = 7.18, SD =
1.55) to 4 weeks (M = 4.94, SD = 1.03) to 8 weeks (M = 1.94, SD = 1.14).
Table 2

Post hoc analysis with a Bonferroni adjustment revealed that levels of depression
statistically and significantly decreased from baseline to 4 weeks (M = 2.24, 95% CI
[1.30, 3.17], p = .001) and from 4 weeks to 8 weeks (M = 3.00, 95% CI [2.08, 3.92], p =
.001). Figure 5 shows the mean score of depression, spanning from baseline to Week 8. A
statistically significant difference was noted between the means. Statistical significance is
the probability that a relationship between variables is not due to random chance (Wagner
& Gillespie, 2018).
The significance level (the alpha) was set to 0.05%. I used a one-tailed test
because the relationship between variables was being analyzed in one direction (Wagner
& Gillespie, 2018). The significance level was then compared to the p-value (Wagner &
Gillespie, 2018). Statistical significance is present when the p-value is less than 0.05
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(Wagner & Gillespie, 2018). Therefore, the null hypothesis was rejected, and the
alternative hypothesis was accepted.
Figure 5
Mean of Depression Measured at Three Points in Time

Measures of Quality of Life
I conducted a one-way rANOVA to determine whether there were statistically
significant differences in levels of quality of life over the course of an 8-week exposure
to testosterone replacement therapy. Table 3 shows the descriptive statistics for the
dependent variable, quality of life. There were no outliers, and the data were normally
distributed, as assessed by a boxplot and a Shapiro-Wilk test (p > .05). The assumption of
sphericity was not violated, as assessed by Mauchly’s test of sphericity, χ2(2) = 2.44, p =
.296. As mentioned previously in the results section, some statisticians consider
Mauchly’s test a substandard procedure to expose violations of sphericity with it often
failing to detect deviations from sphericity in smaller sample sizes (Kesselman et al.,
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1980; Maxwell & Delaney, 2004; Weinfurt, 2000). Maxwell and Delaney (2004)
recommended that the unadjusted test be avoided due to the extreme sensitivity of the
one-way rANOVA to departures from sphericity. Instead, they recommended
disregarding the result of Mauchly’s sphericity test and utilizing the result of the
Greenhouse-Geisser correction (Maxwell & Delaney, 2004). Therefore, a GreenhouseGeisser correction was applied (ε = 0.870).
The testosterone replacement therapy elicited statistically significant changes in
levels of quality of life over an 8-week period of time, F(1.74, 27.83) = 72.39, p < .001,
partial η2 = .82, partial ω2 = .74, with quality of life levels increasing from baseline (M =
70.29, SD = 7.73) to 4 weeks (M = 79.12, SD = 6.52) to 8 weeks (M = 96.65, SD = 5.67).
Table 3

Post hoc analysis with a Bonferroni adjustment revealed that quality of life levels
statistically and significantly increased from baseline to 4 weeks (M = 8.82, 95% CI
[2.93, 14.72], p = .003) and from 4 weeks to 8 weeks (M = 17.53, 95% CI [12.63, 22.43],
p = .001). Figure 6 shows the mean score of quality of life, spanning from baseline to
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Week 8. A statistically significant difference was noted between means. Therefore, the
null hypothesis was rejected and the alternative hypothesis was accepted.
Figure 6
Mean of Quality of Life Measured at Three Points in Time

Evaluation of Repeated Measures ANOVA Assumptions
I conducted a one-way rANOVA to determine if there were significant
differences in the levels of depression and quality of life over the course of 0, 4, and 8
weeks. The first step was to determine if the data had outliers and check to see if the data
were normally distributed (Girden, 1991). There were no outliers in the data as assessed
by inspection of a boxplot. I made use of the Shapiro-Wilk test of normality due to the
sample size being considered small, or under 50 participants (see Girden, 1991). It is
acceptable to run a single normality test for an analysis and to solely rely on that
particular result (Girden, 1991; Wagner & Gillespie, 2018). Looking under the
significance column of the Shapiro-Wilk test it was noted that all numbers were more
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than .05 (p > .05), which indicated that the data were normally distributed. Both
depression and quality of life levels were normally distributed at each point of time
(baseline, 4 weeks, and 8 weeks), as assessed by Shapiro-Wilk’s test (p > .05).
The second step was to carry out the one-way rANOVA with a post hoc test
(Girden, 1991). This route was appropriate to investigate all possible pairwise
comparisons, which are displayed in Tables 4 and 5. While a variety of post hoc tests
exist, the one most suitable for assessing all pairwise comparisons in a one-way
rANOVA involves running multiple paired-samples t-tests along with a Bonferroni
adjustment for multiple comparisons (Girden, 1991).

Table 4

Table 5
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The third step was to interpret and determine whether the assumption of sphericity
was violated (see Girden, 1991; Kesselman et al., 1980; Maxwell & Delaney, 2004;
Weinfurt, 2000). Mauchly’s test of sphericity was not statistically significant (p > .05),
indicating that the assumption of sphericity was met, and not violated for both dependent
variables: depression and quality of life (Girden, 1991; Kesselman et al., 1980; Maxwell
& Delaney, 2004; Weinfurt, 2000). As suggested by some statisticians (Girden, 1991;
Kesselman et al., 1980; Maxwell & Delaney, 2004; Weinfurt, 2000), I ignored Mauchly’s
test and assumed that sphericity was in all likelihood violated.
The fourth step was to analyze and report the effect size (Girden, 1991). Several
different measures of effect size exist for a one-way rANOVA and there does not seem to
be a universal or global preference (Girden, 1991; Wagner & Gillespie, 2018; Weinfurt,
2000). Typically speaking, the estimate of the population effect size is preferred to the
sample effect size (Stevens, 2007). The estimate of the population effect size (partial
ω2), is the estimated value of partial η2 in the population (Girden, 1991; Stevens, 2007).
SPSS does not report partial ω2 but it can be calculated using a formula provided to
statisticians labeled in Figure 7 (Keppel and Wickens, 2004). The value of partial ω2 is
lower than the partial η2 because the partial ω2 compensates for bias (Keppel and
Wickens, 2004).
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Figure 7
Formula for Calculating the Population Effect Size

The fifth step was to interpret and report the post hoc tests with a Bonferroni
adjustment (Girden, 1991; Stevens, 2007). After determining the one-way rANOVA was
statistically significant (p < .05) for both variables, post hoc tests were utilized to
determine where the differences between levels of the within-subjects factor lie (Girden,
1991). There was a decrease in levels of depression from baseline (M = 7.18, SD = 1.55)
to 8 weeks into the testosterone treatment (M = 1.94, SD = 1.14), a statistically
significant mean decrease of -5.24, 95% CI [3.93, 6.54], p < .001 (see Table 4). There
was an increase in levels of quality of life from baseline (M = 70.29, SD = 7.73) to 8
weeks into the testosterone treatment (M = 96.65, SD = 5.67), a statistically significant
mean increase of 26.35, 95% CI [19.44, 33.27], p < .001 (see Table 5). There were
statistically significant differences between the means for both variables (depression and
quality of life). The end result was rejecting the null hypotheses and accepting the
alternative hypotheses.

67
Summary
The RQs addressed in this study were (a) Is the psychological aspect of quality of
life significantly affected by testosterone replacement therapy maturation and (b) Is the
psychological aspect of depression significantly affected by testosterone replacement
therapy maturation? The results of this research study indicate there were statistically
significant differences in the levels of depression and quality of life for males under the
age of 50 suffering from secondary hypogonadism. Overall, the men who participated in
the testosterone replacement therapy reported feeling decreased levels of depression and
increased levels of quality of life as the duration of the testosterone replacement therapy
lengthened. In Chapter 5, I provide an interpretation of my findings, examine the
limitations, make recommendations, analyze the implications and conclude with thoughts
of my study in its entirety.
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Chapter 5: Discussion, Conclusions, and Recommendations
Introduction
The purpose of this quantitative study was to investigate the psychological effects
of testosterone replacement therapy for males under the age of 50 with secondary
hypogonadism. While conducting the literature review for this study, I discovered a lack
of previous research on this specific topic. Although researchers have found that
depression and poor quality of life are associated with testosterone replacement therapy
among older men with secondary hypogonadism (see Busnelli et al., 2017; Cohen et al.,
2020; Dudek et al., 2017; Hackett, 2016; Huo et al., 2016; Mascarenhas et al., 2016; Nian
et al., 2017), they have overlooked the psychological effects for younger males. In the
minimal amount of research that exists on the younger male population with secondary
hypogonadism, the primary focus has been on the sexual and somatic effects of the
testosterone replacement therapy (e.g. Hackett, 2016; Huo et al., 2016; Hwang & Miner,
2015; Morales et al., 2015; Yassin et al., 2016). Academics within the field of clinical
psychology have done minimal to no research, according to my review of the literature,
on the psychological effects of testosterone replacement therapy for younger males with
secondary hypogonadism. I conducted this study to address this gap in the literature.
The study featured a quantitative, non-experimental design that involved analysis
of secondary data to assess the psychological aspects of a male’s life including symptoms
of depression and the quality of life (Akturk & Nippolt, 2016; Aydogan et al., 2012; Huo
et al., 2016; Hwang & Miner, 2015; Javed et al., 2015; Lasaite et al., 2016; Morales et al.,
2015; Shiraishi et al., 2014; Uddin et al., 2017). I used the PHQ-9 (Chen et al., 2016;
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Manea et al., 2015; Mitchell et al., 2016) to operationalize, diagnose, monitor, and
measure perceived levels of depression in patients. I also utilized the QoLS (Burckhardt
& Anderson, 2003) to operationalize and measure quality of life in patients.
I analyzed the independent variable (time exposed to testosterone replacement
therapy measured at baseline, 1 month, and 2 months) was analyzed alongside the two
dependent variables (quality of life and depression). Two separate one-way rANOVAS
were conducted to determine whether there were statistically significant differences in the
levels of depression and quality of life over the course of an 8-week exposure to
testosterone replacement therapy. This study found that as time progressed, men under
the age of 50 with secondary hypogonadism who partook in ongoing testosterone
replacement therapy generally reported decreased levels of depression and increased
levels of quality of life.
Interpretation of the Findings
This study contributes to the research and literature by offering further evidence
of the efficacy of testosterone replacement therapy for males under the age of 50 who
suffer from various negative psychological symptoms. Previous research suggested the
benefit of using testosterone replacement therapy for the aging male population and
indicated the need for studies to further the investigation with the younger male
populations (Hackett, 2016; Huo et al., 2016; Izzo, 2016; Konaka et al., 2016; Lee &
Tillman, 2016). I addressed this gap in the literature by examining the psychological
benefits of testosterone replacement therapy for males under the age of 50 with secondary
hypogonadism (Hackett, 2016; Huo et al., 2016; Izzo, 2016; Konaka et al., 2016; Lee &
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Tillman, 2016). I did so by analyzing secondary data for males receiving testosterone
replacement therapy.
As mentioned in Chapter 2, previous researchers differed in their views
concerning the efficacy of testosterone replacement therapy (Shiraishi et al., 2014; Uddin
et al., 2017). The scholarly research currently available tends to focus on the relationship
of testosterone levels for males over 50 years of age (Aydogan et al., 2012; Huo et al.,
2016; Lasaite et al., 2016). Some of the literature mentions males under the age of 50 in
relation to testosterone replacement therapy but focuses more on the sexual and somatic
issues (Aydogan et al., 2012; Dhindsa et al., 2018; Hackett, 2016; Huo et al., 2016;
Hwang & Miner, 2015; Morales et al., 2015; Yassin et al., 2016). The literature review
yielded mixed findings, which suggested variations in study design and demographics
(Akturk & Nippolt, 2016; Aydogan et al., 2012; Huo et al., 2016; Hwang & Miner, 2015;
Javed et al., 2015; Lasaite et al., 2016; Morales et al., 2015; Shiraishi et al., 2014; Uddin
et al., 2017). This study focused on the relationship between the independent variable
(time exposed to testosterone replacement therapy) and the dependent variables
(depression and quality of life).
The findings of this study are consistent with those of researchers who reported
that testosterone replacement therapy may psychologically benefit males of any age
(Aydogan et al., 2012; Huo et al., 2016; Lasaite et al., 2016; Morgentaler et al., 2016).
Data provided for this study suggest that males under the age of 50 with secondary
hypogonadism tend to see significant decreases in levels of depression and significant
increases in quality of life levels. These findings build upon previous studies by showing
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that psychological benefits of testosterone replacement therapy are effective for males
under the age of 50. This study addressed the gap in the literature and helps provide
clarification, options, and avenues for social change by supplying new information on a
viable treatment method. This study is important in practice because it substantiates the
benefits of utilizing testosterone replacement therapy to provide solace to males under the
age of 50 with secondary hypogonadism. This benefit continues beyond the individuals
being treated with testosterone replacement therapy, and extends into the fields of
medicine and psychology where it provides knowledge of a medical issue that mimics
various negative psychological symptoms.
Limitations of the Study
External Validity
External validity, also known as generalizability, is the extent to which the results
of this study are generalizable to other individuals and circumstances (FrankfortNachmias et al., 2015; Lesko et al., 2017). Repeated measures, such as the one used in
my study, do not typically impact external validity (Dannels, 2018; Frankfort-Nachmias
et al., 2015). The results of this study are difficult to generalize due to the intended
population and the limitation of the data collection. I analyzed data from a regional
facility which represented an unknown percentage of individuals with secondary
hypogonadism who made the decision to visit a health clinic. The deidentified secondary
data I received did not offer any information relating to race, ethnicity, or previous
medical/mental health conditions. The identifying factors were limited to age, gender,
type of hypogonadism, and testosterone levels.
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I did not have access to all populations of interest. The representative sample was
small and may not accurately represent males under the age of 50 with secondary
hypogonadism on a global level. The accessible population was the portion of the
population to which I had access via secondary data gathered from one particular region
in the United States. The sample gathered was a reflection of the population served by the
study clinic; it is not reflective of other regions of the United States or other countries in
the world.
Frankfort-Nachmias et al. (2015) pointed out that using secondary data is also
considered a limitation. With secondary data, an inability exists in controlling how the
data are gathered, generated, and recorded (Frankfort-Nachmias et al., 2015). Relying on
other individuals to gather information accurately is an unknown, which may be a
limitation to this study’s validity (Frankfort-Nachmias et al., 2015).
Internal Validity
Internal validity is the extent to which the effects of a study are due to the
manipulation of the independent variable and not something else (Creswell, 2014;
Frankfort-Nachmias et al., 2015). Repeated measures designs tend to have a strong
statistical power (Creswell, 2014; Frankfort-Nachmias et al., 2015). This strength is due
to an increased number of data points being gathered from the same number of
participants (Creswell, 2014; Frankfort-Nachmias et al., 2015). Within-subjects designs
tend to have more statistical power than when compared to a between-subjects design
(Creswell, 2014; Frankfort-Nachmias et al., 2015).
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The duration that the participants were exposed to testosterone replacement
therapy is a possible limitation of this study. Psychological researchers tends to measure
in increments of 6 months to 1 year, with medical measurements typically occurring at 3
months, 6 months, and biannually after that (Cherrier et al., 2015; Corona et al., 2016;
Izzo et al., 2016; McCullough, 2015). This limitation is important to note because 4 to 8
weeks on testosterone replacement therapy may suggest a correlation, but it does not
automatically equate to causation.
I used an experimental group so a variety of potential threats arose for internal
validity (Creswell, 2014; Frankfort-Nachmias et al., 2015). Maturation effects were
analyzed but deemed not applicable. A maturation effect happens when alterations in a
score over the course of time are attributed to naturally-occurring internal processes
(Blalock, 2018; Dannels, 2018). Males diagnosed with secondary hypogonadism have to
either supplement their testosterone because their body is faulty and not producing
adequate amounts, or go without.
I analyzed history effects. These may be a possible threat because they take into
account external events that may have occurred between the measurements. For example,
this study took place in the spring, and as the weather got nicer, perhaps some or all of
the participants started spending more time outside, which in turn may have been
partially responsible for improving moods.
I also analyzed testing effects and deemed it a possible threat. Perhaps the
questions asked at baseline (before the testosterone replacement therapy started) primed
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the participants in some way. It is possible that the baseline measurement affected how
the participants answered the follow-up questionnaires in weeks 4, and weeks 8.
I analyzed instrument decay but deemed it not applicable because the decay
happens when the standards of a measuring device change over the course of time. The
assessments used to measure depression and quality of life have not changed in years,
and the exact same assessments were utilized during baseline, week 4, and week 8
(Burckhardt & Anderson, 2003; Chen et al, 2016; Manea et al., 2015; Mitchell, et al.,
2016). Furthermore, the exact same measurements were utilized during baseline, Week 4,
and Week 8.
I analyzed statistical regression toward the mean but it was deemed not
applicable. Statistical regression would convey that the participants were chosen based on
extreme scores, which they were not. Although it is true the participants all had
confirmed low levels of testosterone before partaking in the study, it was not confirmed
whether or not the participants had decreased levels of quality of life and depression.
I analyzed self-report response bias and deemed it a conceivable threat, as it was
possible the participants provided inaccurate or false responses to questions. It is possible
that a placebo effect took place. The participants came in expecting testosterone
replacement therapy and were given the questionnaires relating to depression and quality
of life before they were given the first treatment dosage. It is possible that the participants
felt pressure or some type of demand during Weeks 4 and 8 to demonstrate through the
questionnaires increased levels of quality of life and decreased levels of depression.
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I analyzed demand characteristics and deemed them a possible threat because
sometimes participants expect they are being evaluated, which can result in them trying
to attain particular scores (Allen, 2017). Demand characteristics cannot be completely
eliminated, although decreasing their impact on research results is possible (Allen, 2017).
Due to the data collection method being secondary, reducing or controlling for the
potential impact of demand characteristics was not possible.
Recommendations
To strengthen the reliability and generalizability, future researchers and
academics could take into account and evaluate possible variances based on location, age,
and timeframe. Future researchers could also run an experimental design and have a
control group. In addition, they could analyze and take into account the relationships
between the participants’ ethnicity, current medical conditions, mental diagnoses, and
other markers that may affect results. Future researchers could also run a longitudinal
study and set the measuring points 1, 2, 5, or 10 years apart from one another. Future
researchers could even analyze various methods to administer testosterone and see if
there is a correlation or relationship between the methods and the outcomes.
This study was not able to provide conclusive evidence for explanations of
causation. It does appear though, that a correlation exists between time exposed to
testosterone replacement therapy and improved perceptions of quality of life and
decreased levels of depression. This study is at the beginning of research exploration for
psychologists looking to learn and discover more about the psychological benefits of
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testosterone replacement therapy for men under the age of 50 with secondary
hypogonadism.
Additionally, research psychologists could explore the qualitative impact of how
testosterone replacement therapy affects the family members of men under the age of 50
diagnosed with secondary hypogonadism. The newness of this study requires continuing
research to assist in uncovering useful information to an underserved population. With
respect to furthering the understanding of the benefits of testosterone replacement therapy
for men under the age of 50 with secondary hypogonadism, recommendations can be
made for future research based on the limitations discussed earlier in Chapter 5. This
study is then able to be used to guide future research which can allow for more detailed
assertions of testosterone replacement therapy as a beneficial treatment for males with
secondary hypogonadism.
First, I recommend that this study be conducted again with the involvement of
more medical clinics and participants so that the sample size will be larger and more
robust. Second, I recommend that this study be conducted again taking into account
longer periods of measurement than what the current secondary data provided. Measuring
at 6 months, 1 year, 2 years, 5 years, and 10 years may provide additional insight
regarding participants’ levels of quality of life and depression. More specific data may
also allow researchers to analyze various influencing factors including but not limited to:
pituitary disorders, inflammatory disease, medications, obesity, and malnutrition.
Additional dependent variables could be analyzed as well including but not limited to:
anxiety, aggression, and stress.
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Implications for Positive Social Change
The intention of this study was to investigate the psychological effects of
testosterone replacement therapy for males under the age of 50 with secondary
hypogonadism. Synthetic testosterone was created to help mitigate the negative effects
for those individuals with naturally low testosterone (Nieschlag, & Nieschlag, 2019). As
the most essential male hormone, testosterone has an impact on almost all human organs
(Nieschlag, & Nieschlag, 2019). The results of this study address the misconception that
low testosterone exclusively correlates with age and provides a deeper understanding of
the positive psychological effects of testosterone replacement therapy for males under the
age of 50 with secondary hypogonadism (Aydogan et al., 2012; Basaria, 2014;
McCullough, 2015). The potential implications for positive social change includes
contributing to and furthering scientific knowledge and awareness in the field of
psychology, by way of investigating the psychological effects of testosterone replacement
therapy for males under the age of 50 diagnosed with secondary hypogonadism.
The results of this study brings awareness to an existing population of younger
males who acquire hypogonadism due to malfunctions of the pituitary gland or
hypothalamus (Dudek et al., 2017; Forni & Wray, 2015; Lee & Tillman, 2016). The more
knowledge is available to males, the better informed they will be when making a decision
whether or not to partake in testosterone replacement therapy. The findings of this
research also bring awareness to scholars and professionals in fields of both medicine and
psychology of a medical issue that mimics psychological symptoms including depression,
anxiety, and various other DSM-5 diagnoses (Issacs & Thomas, 2015; Kim et al., 2016;
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Lee & Tillman, 2016; Samahy et al., 2021; Veras & Nardi, 2010). The findings of this
research also bring awareness to neuropsychologists, neurologists, endocrinologists, and
internal medicine specialists of a medical issue that can result from traumatic brain injury
or mimic its symptoms (Issacs & Thomas, 2015; Sterling et al., 2015; Tanriverdi et al.,
2015). It is important for psychologists and neuropsychologists to keep in mind the
relevance of a patient’s medical history before considering a diagnosis (Issacs & Thomas,
2015; Lee & Tillman, 2016). Education and awareness of low testosterone issues allows
for increased accuracy of diagnoses (Issacs & Thomas, 2015; Lee & Tillman, 2016).
Implications of this study start small and will continue to grow larger. The health
clinic that provided the secondary data for this study requested results so they could
provide scientific backing of their work to potential clients. The health clinic that
provided the secondary data also expressed future interest in co-researching and coauthoring several additional longitudinal studies, each looking at various psychological
benefits of testosterone therapy for males with secondary hypogonadism. A psychology
convention taking place in France in Spring of 2023 also expressed an interest in having
the findings of this study shared. It is my intention that increasing the numbers of
providers and clinicians within the psychological community who are educated on
hypogonadism, will create a deeper understanding of the importance of collaborative care
and furthering education. The results of this study promote continuing psychological and
medical breakthroughs and support for this underserved population (Issacs & Thomas,
2015; Lee & Tillman, 2016). This study has the potential to impact both fields of
medicine and psychology.
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Conclusion
Men under the age of 50 who present to their medical providers with symptoms of
depression should be offered a blood test as part of the lab work to rule out whether or
not secondary hypogonadism is a possible contributing factor. Men under the age of 50
who present to their mental health providers with symptoms of depression should be
pointed in the direction of their general practitioner and given a recommendation to have
their blood tested for testosterone levels to rule out whether or not secondary
hypogonadism is a possible contributing factor.
This study contributes to the literature gap, looking at the psychological benefits
of testosterone replacement therapy for males under the age of 50 with secondary
hypogonadism while providing ideas and areas for future research (Hackett, 2016; Huo et
al., 2016; Izzo, 2016; Konaka et al., 2016; Lee & Tillman, 2016). The results between
each period of time (baseline, 4 weeks in, and 8 weeks in) suggest increases in the
reported quality of life levels as well as decreases in the reported levels of depression.
These findings are not only relevant to those individuals who are diagnosed with
secondary hypogonadism, but to the medical, neurological, and psychological providers
in general.
The findings of this study remind medical, neurological, and psychological
professionals to be mindful of patient issues that span multiple realms as explained with
the biopsychosocial model (Engel, 1977; Jorn, 2015; Vongas & Alhaji, 2015; Wade &
Halligan, 2017). This study has demonstrated with statistical and clinical significance,
that men under the age of 50 who have been diagnosed with secondary hypogonadism,
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and who are being treated with testosterone replacement therapy, experience increased
levels of quality of life and decreased levels of depression.
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Appendix B: Key Words Used to Locate Literature for the Study
The following is an exhaustive list of key words, terms, and phrases used during the
current research project: testosterone, free testosterone, bioavailable testosterone, low
testosterone, testosterone restoration, gonadotropin, hypopituitarism, hypogonadism,
hypogonadal, hypogonadotropic hypogonadism, primary hypogonadism, secondary
hypogonadism, central hypogonadism, late-onset hypogonadism, testosterone
replacement, testosterone replacement therapy, testosterone therapy, testosterone levels,
testosterone deficiency, testosterone effects, low testosterone, low testosterone levels,
pituitary dysfunction, pituitary gland disfunction, pituitary hormone dysfunction,
pituitary-gonadal dysfunction, hypothalamus disfunction, hypothalamic dysfunction,
hormones, androgens, brain injury, traumatic brain injury, men, males, age, young,
younger, middle-aged, older, elderly, endocrinology, neuroendocrine,
neuroendocrinology, internal medicine, depression, quality of life, Patient Health
Questionnaire, Quality of Life Scale, biopsychosocial, psychological, impact of, benefits
of, effect of, risks, implications, reliability, validity, utilization, treatment, literature
review, peer-reviewed, seminal, review articles, systematic reviews, empirical studies,
and meta-analysis.
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Appendix C: Instrumentation Used for Operationalization of Constructs
I included two instruments, the PHQ-9 and the QoLS. Kroenke et al. (2001)
developed the PHQ-9 with funding from Pfizer. Permission to use the instrument is not
necessary because it is in the public domain.
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Flanagan developed the QoLS in the 1970s (Burckhardt & Anderson, 2003; Gupta
& Venkatesan, 2018). Permission to use this instrument is not necessary because it is in
the public domain.

